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SUMMARY 
 
Lung function is critically dependent on the integrity of the pulmonary epithelial 
cell layer, which is largely comprised of bronchial, Clara, and type I and II alveolar 
epithelial cells (AEC). While primary AEC culture has increased our knowledge of 
AEC gene expression in vitro, a comprehensive analysis of epithelial cell gene 
transcription in vivo has not yet been attempted. Therefore, we sought to profile the 
epithelial cell gene expression in the murine lung in vivo. We established a method to 
obtain epithelial cell RNA-enriched fractions using a diluted guanidinium 
isothiocyanate solution, administered intratracheally. After lavaging the lungs twice 
with saline, the optimal dilution and retention time were optimised. This resulted in an 
enriched epithelial cell RNA fraction with low contamination by RNA from fibroblasts, 
smooth muscle, or endothelial cells, as assessed by marker gene expression. This novel 
methodology, named as epithelial lavage (EL), thus allows for the selective profiling of 
lung epithelial-specific gene expression patterns in vivo.  
Furthermore, in order to mimic the high levels of transforming growth factor 
beta 1 (TGF-β1), a cytokine expression of which is dramatically upregulated in the 
lungs of patients with idiopathic pulmonary fibrosis (IPF), the recombinant TGF-β1 was 
instilled into the murine lung. It was demonstrated that the orotracheal (OT) 
administration of TGF-β1 stimulated Smad-dependent signalling in pulmonary 
epithelial cells, and induced transcription of TGF-β1-responsive genes. The activation 
of the downstream signalling pathway, assessed by Western blotting, microarray, and 
reverse transcriptase-polymerase chain reaction (RT-PCR) from lung homogenates, was 
achieved within short stimulation time-points and with either low or high concentrations 
of TGF-β1.  
Moreover, TGF-β1-induced gene transcription was studied specifically to the 
lung epithelium in vivo after OT administration of TGF-β1 in combination with the EL 
methodology. A single dose of TGF-β1 stimulated the regulation of some markers after 
8 h, as assessed by quantitative RT-PCR, demonstrating induction or inhibition in 
expression of various epithelial gene expressing markers in vivo. Therefore, the EL 
technique represents a novel methodology to isolate RNA from the lung epithelium and 
study the gene expression profile of these cells under different conditions, like the TGF-
β1 effect assessed in this study.  
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ZUSAMMENFASSUNG 
 
Die Funktion der Lunge hängt wesentlich von der Intaktheit der Epithelschicht 
ab, welche hauptsächlich aus Bronchialzellen als auch aus Clarazellen und TypI und 
TypII Pneumocyten, den Alveolarepithelzellen, besteht. Während mit Hilfe der 
Zellkultur von primären Zellen bereits viel über die Genexpression in Pneumocyten in 
vitro erforscht werden konnte, wurde bisher noch keine weitergehende Studie über die 
Genexpression im Lungenepithel in vivo durchgeführt. Deshalb haben wir in unserer 
Studie die Genexpression von Epithelzellen der Mauslunge in vivo untersucht. Wir 
etablierten eine Methode, bei der RNA-Fraktionen aus dem Lungenepithel gewonnen 
werden, indem verdünntes Guanidinisothiocyanat intratracheal in die Mauslunge 
appliziert wird. Nachdem die Lunge zwei mal mit Salzlösung gespült worden war, 
wurden die Verdünnung und die Verweilzeit der Lösung in der Lunge optimiert. 
Dadurch erhielten wir eine Fraktion, die mit epithelialer RNA angereichert war, mit 
geringer Kontamination durch RNA von Fibroblasten, glatten Muskelzellen oder 
Endothelzellen. Dies zeigten wir durch die Untersuchung der Expression von 
Markergenen. Diese neue Methode, Epitheliale Lavage (EL) genannt, ermöglicht also 
eine selektive Darstellung der Expressionen von lungenepithelspezifischen Genen in 
vivo. 
Um die hohen Konzentrationen des transforming growth factor beta 1 (TGF-β1) zu 
imitieren, einem Zytokin, dessen Expression in der Lunge von Patienten mit 
idiopathischer Lungenfibrose (IPF, Idiopathic Pulmonary Fibrosis) stark hochreguliert 
ist, wurde TGF-β1 als rekombinantes Protein in die Mauslunge instilliert. Dadurch 
konnte gezeigt werden, dass eine oro-tracheale Administration von TGF-β1 den 
intrazellulären Smad-abhängigen Signaltransduktionsweg in den Lungenepithelzellen 
stimuliert, sowie die Expression der Gene, die durch TGF-β1 aktiviert werden. Die 
Aktivierung der nachgeschalteten Signalwege wurde bereits nach kurzer 
Stimulationszeit sowie mit niedrigen und hohen Konzentrationen des Liganden TGF-β1 
durch Westernblot, Microarray und semi-quantitativen RT-PCR den 
Lungenhomogenaten nachgewiesen.  
Wir untersuchten weiter die TGF-β1-induzierte Gentranskription in dem 
Lungenepithelium in vivo nach orotrachealer Applikation von TGF-β1 in Kombination 
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mit der epithelialen Lavage-Technik. Acht Stunden nach einer einmaligen Gabe von 
TGF-β1 konnten wir mit Hilfe der quantitativen RT-PCR einen Effekt auf die 
Regulation der Expression einiger Marker feststellen. Dadurch konnten wir die TGF-
β1-regulierte Induktion der Genexpression im Lungenepithel in vivo zeigen. Aufgrund 
unserer Ergebnisse konnten wir zeigen, dass EL eine neue Methode darstellt, RNA aus 
dem Lungenepithel zu isolieren und das Genexpressionsprofil dieser Zellen unter 
verschiedenen Bedingungen zu untersuchen, wie der Effekt von TGF-β1 in der 
vorliegenden Studie.  
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1 INTRODUCTION 
 
General 
The lung is the organ that makes our respiration possible, being continuously 
exposed to air that contains a variety of infectious, inflammatory, and toxic agents. The 
host and the environment meet at the respiratory acini, a site of possible bacterial 
colonization. Therefore, the diseases of the respiratory system have become a major 
challenge in medical care, causing multiple socio-economic problems. The incidence of 
genetic and malignant lung diseases is steadily increasing. According to the World 
Health Organisation (WHO), of the top ten leading causes of mortality worldwide, four 
are diseases of the lung: tuberculosis, chronic obstructive pulmonary disease (COPD), 
pneumonia, and lung cancer. In Europe, respiratory diseases rank second after 
cardiovascular diseases in terms of mortality, incidence, prevalence, and costs (Murray 
and Lopez, 1997). 
Modern medicine is faced with great difficulties treating pulmonary illnesses. 
Pneumonia is the most frequent lethal infectious pathology of all infectious diseases 
described, with 17,000 fatal cases per year in Germany alone. Acute lung injury (ALI) 
and pneumogenic sepsis represent the most common hospital-acquired diseases leading 
to death. The flu, caused by influenza viruses, reaches 12,000 deaths per year in 
Germany. Furthermore, fibrotic lung diseases, totalling almost 80,000 cases in Germany 
is without any therapeutic option, a fatal disease (Loddenkemper et al., 2003).  
The onset and natural history of such diseases are dependent on individual 
genetic predispositions, cigarette smoke, and environment, among others. The 
molecular mechanisms of several genetic diseases are now starting to be unravelled. 
This will facilitate the development of new drugs that can prevent, treat, and cure 
respiratory illnesses. 
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1.1 ACTIVE SIGNALLING IN THE LUNG 
1.1.1 Transfrorming growth factor-beta (TGF-β) superfamily 
The transforming growth factor-beta (TGF-β) superfamily of ligands controls a 
large number of processes including cell proliferation, lineage determination, cell 
differentiation, adhesion, motility, and death. This family of cytokines plays a major 
role in the development, homeostasis, angiogenesis, and repair of most tissues in 
metazoan organisms (Massague, 1998). It comprises a large number of 
structurally-related proteins, such as the TGF-β ligands themselves, bone 
morphogenetic proteins (BMPs), the activins and inhibins, and other growth and 
differentiation factors (GDFs) (Mehra and Wrana, 2002; Miyazawa et al., 2002). 
The term transforming growth factor (TGF) was coined in the early eighties, and 
it was applied to peptides that had the ability to confer a transformed phenotype on 
untransformed fibroblastic cells in vitro. Two different classes of TGF were defined: the 
alpha (TGF-α) and the beta (TGF-β) (Roberts and Sporn, 1985). While TGF-α is 
related to epidermal growth factor (EGF) and binds to the EGF receptor, TGF-β is not 
structurally or functionally related either to TGF-α or EGF, and binds to different 
receptors (Coffey et al., 1992). 
Briefly, TGF-β and related factors transmit signals in the cell as follows: upon 
ligand binding to the type I and type II serine/threonine transmembrane kinase 
receptors, activation of the receptor-associated cytoplasmic effector molecules, Smads 
occurs. The receptor Smad (R-Smad) phosphorylation leads to association with the 
common Smad (Co-Smad), also known as Smad4. This transcription factor (TF) 
complex then translocates into the nucleus, where it activates or represses gene 
transcription, in association with DNA-binding partners (Figure 1.1). 
Although this pathway appears to be simple, the combinatorial interactions,  for 
example between the receptors themselves and with the R-Smads, allows enormous 
diversity in the TGF-β cell responses (Derynck and Zhang, 2003). Moreover, the 
differential effects on the cell depends on ligand concentration, the activated 
downstream molecules, and on the responsiveness of the target cell (Massague, 2000). 
For instance, in epithelial cells, the TGF-β ligands inhibit cell growth and induce 
differentiation including epithelial-to-mesenchymal transition (EMT); whereas BMP 
ligands weakly induce epithelial cell growth and do not induce cell differentiation 
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(Derynck and Zhang, 2003; Kowanetz et al., 2004). Moreover, the TGF-β1 ligand can 
bind to various type I receptors, either the ALK-1 (solely expressed in endothelial cells) 
or ALK-5, inducing Smad1/5/8 or Smad2/3 phosphorylation, respectively and 
subsequently, diverse responses inside the cell are driven (Lebrin et al., 2005). 
 
 
 
 
 
 
 
 
 
Figure 1.1: Schematic diagram of the TGF-β signalling pathway from the cell membrane to the 
nucleus. The arrows indicate signal flow. At the cell surface, the ligand binds to the type I / type II 
receptor complex and induces phosphorylation of the GS segment (red) in the type I receptor. 
Consequently, R-Smad are phosphorylated at the C-terminal serines, and then form a complex with 
Smad4. This complex translocates into the nucleus to regulate transcription of target genes, assisted by 
either co-activators or co-repressors. R-Smads and Smad4 shuttle between the nucleus and the cytoplasm. 
Smurf1, Smurf2, Smad6, and Smad7 function as inhibitors of TGF-β signalling (after Derynck and 
Zhang, 2003).  
1.1.1.1 TGF-β ligands 
A large number of ligands are present in the TGF-β superfamily with the same 
structural profile: a dimer (homo- or heterodimer) held together by hydrophobic 
interactions (Sun and Davies, 1995). The TGF-β ligands are synthesised as propeptide 
precursors, and are then processed and secreted as inactive homodimers, noncovalently 
bound to a latency-associated peptide (LAP) (Massague, 1998). The latent form 
becomes active extracellularly through proteolysis by thrombin and plasmin or 
retinoids, tissue transglutaminase, reactive oxygen species (ROS), low pH and 
thrombospondin (Camoretti-Mercado and Solway, 2005). The ανβ6 integrin-expressing 
cells also induce spatially restricted activation of TGF-β1 (Munger et al., 1999). The 
ανβ6 integrin is principally expressed by epithelial cells, at low levels in healthy adult 
lung tissues and highly and rapidly upregulated in injury and inflammatory conditions 
(Breuss et al., 1995). 
Three distinct TGF-β isoforms are secreted in mammals (TGF-β1, 2 and 3), 
which are encoded by different genes, and exhibit diverse expression patterns in vivo, 
due at least in part to differences in their promoter regions (Taipale et al., 1998). The 
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TGF-β1 isoform is induced by oncogenes and immediate early genes, whereas the other 
two isoforms are more developmentally and hormonally regulated (Letterio and 
Roberts, 1996). The diversity in biological activity correlates with the binding affinity 
of the ligands to the different TGF-β receptors (Wrana et al., 1992) and with the 
assembled accessory receptors, such as endoglin and betaglycan (Massague, 1998).  
Specifically, the TGF-β1 isoform is produced by a large variety of cell types, 
such as, platelets and immune cells including lymphocytes, macrophages, and mast 
cells. Specifically in the lung, the endothelial, and smooth muscle cells (SMC), 
fibroblasts and epithelial cells synthesise this cytokine. Infiltrated inflammatory cells, 
including eosinophils and lymphocytes, also secrete TGF-β1 under stress conditions 
(Duvernelle et al., 2003). Interestingly, the TGF-β1 isoform has been implicated in 
diverse human pathologies, such as parasitic, autoimmune and fibroproliferative 
diseases, affecting distinct organs like the kidney, lung and liver (Border and Ruoslahti, 
1992; Wahl, 1994). Therefore, the TGF-β1 isoform has been deeply studied during the 
last two decades, mainly for its role in inflammatory responses and healing disorders.  
1.1.1.2 TGF-β receptors: classification and structure 
The TGF-β receptor family comprises highly conserved transmembrane protein 
serine/threonine kinases (Krishnaveni and Eickelberg, 2006). Based on their structural 
and functional properties, the signalling receptors are divided into two subfamilies: type 
I (or activin receptor-like kinase, ALK-1 to -7) and the constitutively-active type II 
receptors, like the TβRII and BMPRII (de Caestecker, 2004). In mammals, five type II 
receptors and seven type I receptors have been identified. All of them contain a short 
extracellular domain, a cytoplasmic kinase domain, and in the case of type I receptors, 
additionally possess a GS domain, which is phosphorylated by the type II receptors, 
activating the signalling complex (Massague, 1998) (Figure 1.1 and 1.2). Upon ligand 
binding, the heterotetrameric receptor complex is formed, composed of two molecules 
each of type I and type II receptors (Kirsch et al., 2000). The possible combinations 
bridging the several type I and type II receptors together are large (Figure 1.2). 
Additionally, two accessory receptors called betaglycan and endoglin, classified as type 
III receptors, facilitate ligand binding (Krishnaveni and Eickelberg, 2006; Lutz and 
Knaus, 2002).  
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Figure 1.2: Overview of the combinatorial interactions between type I and type II TGF-β signalling 
receptors and their corresponding R-Smads. Only the best-characterised interactions are listed (after 
Derynck and Zhang, 2003). 
1.1.1.3 Intracellular signalling molecules: Smads 
Activated type I receptors subsequently phosphorylate their cytoplasmic 
substrates, the Smad proteins. The Smad family of transcription factors, whose name is 
derived from the founding members of this family, the Drosohila melanogaster protein 
MAD (Mothers Against Decapentaplegic) and the Caenorhabditis elegans protein SMA 
(Small Body Size), is composed of eight proteins, Smad1-8, divided into three 
subclasses based on their structure and function (Miyazawa et al., 2002; Moustakas et 
al., 2001): 
i) Receptor-regulated Smads (R-Smads): Smad1, Smad2, Smad3, Smad5, and 
Smad8. 
The R-Smads are the receptor-associated cytoplasmic effector molecules, which 
are directly phosphorylated by the type I receptor kinases. They are subdivided 
in two groups: 1) The activin/TGF-β activated R-Smads, Smad2 and Smad3, are 
also phosphorylated by activin, nodal, ALK-4, -5 and -7 receptors (Macias-Silva 
et al., 1996; Zhang et al., 1996). 2) The BMP activated R-Smads, Smad1, Smad5 
and Smad8, are also phosphorylated by ALK-1, -2, -3, -6 and BMP type I 
receptors (Kretzschmar et al., 1997). 
ii) Common-partner Smad (Co-Smad): Smad4. 
In vertebrates, only one member is contained in this group, the so-called Smad4. 
Smad4 is necessary for the interaction between the R-Smads and various DNA-
binding proteins, and in the activation of gene transcription (Lagna et al., 1996; 
Liu et al., 1997).  
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iii) Inhibitory Smads (I-Smads): Smad6 and Smad7. 
The I-Smads are also called antagonistic Smads. They associate with the 
activated type I receptors in order to prevent R-Smad binding and activation, and 
therefore, inhibiting the signalling cascade. Both the TGF-β/activin and BMP 
signalling pathways are repressed by Smad7 (Hanyu et al., 2001; Nakao et al., 
1997), whereas Smad6 specifically inhibits BMP signalling and competes with 
the Co-Smad in binding to active R-Smads (Hata et al., 1998; Imamura et al., 
1997). The I-Smads are activated by several signals, including TGF-β- and 
BMP-induced negative feedbacks (Ishida et al., 2000). The duration and 
magnitude of the TGF-β / BMP signalling effects are thus determined by the 
Smad6 and Smad7 expression levels (Miyazawa et al., 2002; ten Dijke and Hill, 
2004).  
 
Structurally the Smad molecules contain two well-characterised, highly 
conserved, Mad homology (MH) domains, MH1 and MH2, present at the N- and 
C-terminal ends, respectively. A divergent middle linker segment is flanked by these 
two domains. The MH2 region is present in all three Smad subclasses, whereas the 
MH1 domain is absent in the I-Smads. The phosphorylation target site on the R-Smads 
contains the SSXS (S: serine; X: any amino acid except proline) motif at the C-terminal 
end (Massague, 1998; Moustakas et al., 2001). In the basal state, MH2 domain activity 
is inhibited by the MH1 region by physical association (Hata et al., 1997). Upon ligand 
binding and thus receptor activation, the interaction between both domains is disrupted, 
allowing the R-Smads to form a hetero-oligomer with the Co-Smad through their MH2 
domains (Mehra and Wrana, 2002). 
Once activated and translocated into the nucleus, the MH1 and MH2 domains 
perform different functions. The MH1 region is involved in DNA binding (Kusanagi et 
al., 2001) and the MH2 domain is able to complex with several DNA-binding factors 
and activate or repress gene transcription (Dennler et al., 1998). 
1.1.1.4 Regulation of the TGF-β pathway 
The presence of DNA-binding factors is required in order to achieve high-
affinity, selective interactions with specific DNA-binding sequences. The number of 
DNA-binding partners described thus far is large (Miyazawa et al., 2002). They are 
divided into two groups, co-activators (CBP/p300, SMIF) (Feng et al., 1998; Itoh et al., 
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2000) and co-repressors (c-Ski/SnoN, c-Myc) (Alexandrow et al., 1995; Liu et al., 2001; 
Luo et al., 1999) The co-activators bind to or possess intrinsic histone acetyltransferase 
(HAT) activity, which facilitates gene activation. On the contrary, the co-repressors 
recruit histone deacetylases (HDAC) to the complex, whose effect generally leads to 
chromatin condensation and thus, represses Smad transcriptional activity (Figure 1.4) 
(Berger, 2002; Massague, 2000).  
The negative feedback represents another source of regulation at the intracellular 
level of the TGF-β signalling pathway (Figure 1.1 and 1.4). At the receptor level, 
FK506-binding protein of 12 kDa (FKBP12) binds to type I TGF-β receptor (ALK-5) 
impairing its phosphorylation by the type II TGF-β receptor (TβRII) at the basal state 
(Chen et al., 1997). Furthermore, Smad6 and Smad7 impair the R-Smad binding to the 
corresponding receptors (Stopa et al., 2000). Finally, the ubiquitin ligases, 
Smad-ubiquitination-regulatory factor 1 and 2 (Smurf1 and Smurf2), antagonise TGF-β 
signalling by interacting with the R-Smads and targeting them for degradation (Figure 
1.1 and 1.3) (Arora and Warrior, 2001; Zhu et al., 1999). 
 
 
 
 
 
 
 
 
 
Figure 1.3: A network controlling the TGF-β signalling pathway. Regulation of the TGF-β pathway 
can take place at receptor level by accessory inhibitor proteins (e.g. FKBP12 and BAMBI); downstream 
cytoplasmic molecules by Smad6, Smad7, Smurf1 and Smurf2; and inside the nucleus by co-activators 
and co-repressors (CBP/p300 and c-Ski/SnoN). In addition, crosstalk pathways control TGF-β signaling 
(i.e. Wnt pathway, NF-κB). The blue arrows indicate the agonists, and the green and red arrows indicate 
activation and inhibition of the pathway, respectively (after Massague, 2000). 
1.1.1.5 TGF-β target genes 
TGF-β-induced gene transcription or repression is dependent on the cell type, 
promoter sequence and DNA-binding proteins (Moustakas et al., 2001). The inhibition 
of the cell-cycle progression by TGF-β stimulation in many cell types is 
well-characterised. TGF-β1 induces the activation of p15Ink4b (Hannon and Beach, 
1994) and p21Cip1 (Datto et al., 1995), which are cyclin-dependent kinase (cdk) 
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inhibitors that control the G1 phase. Conversely, TGF-β represses the oncogene c-myc 
(Alexandrow et al., 1995), the Cdk-activating phosphatase cdc25A (Iavarone and 
Massague, 1997) and the inhibitor of differentiation (Id) family. The Id proteins act as 
negative regulators of cell differentiation and positive regulators of cell proliferation 
(Korchynskyi and ten Dijke, 2002; Norton et al., 1998). 
Several other genes are reported to be upregulated upon TGF-β1 ligand binding 
through Smad2/3 activation. Among them, genes encoding plasminogen activator 
inhibitor-1 (PAI-1) (Dennler et al., 1998; Hua et al., 1999), type I collagen (Zhang et al., 
2000), Smad7 (Stopa et al., 2000), JunB (Pertovaara et al., 1989) and connective tissue 
growth factor (CTGF) (Grotendorst et al., 1996). Additionally, TGF-β1 promotes the 
accumulation of many extracellular matrix (ECM) proteins by increasing their synthesis 
while inhibiting the production of matrix-degrading enzymes (Branton and Kopp, 1999; 
Selman et al., 2001). 
1.1.1.6 TGF-β transgenic mice 
Studies on mice harboring null mutations for the different TGF-β isoforms 
revealed that each isoform exerts discrete, nonredundant functions during murine 
development (Goumans and Mummery, 2000). Initially TGF-β1 null-mice suggested 
that the ligand was only required postnatally (Shull et al., 1992); however, further 
reports have proven that transplacental and lactational transfer of maternal TGF-β1 were 
sufficient to rescue the development and growth of the pups (Letterio et al., 1994). 
Different approaches have later shown that TGF-β1 is required for at least two distinct 
phases during embryogenesis; for preimplantation and for the vasculogenesis and 
haematopoiesis of the yolk sack (Kallapur et al., 1999). Moreover, TGF-β1 null-mice 
suffer from an excessive inflammatory response, with massive infiltration of leukocytes 
into many organs resulting in a multifocal inflammatory disease, organ failure, and 
early death (Kulkarni et al., 1993; Shull et al., 1992). The heart and the lungs were the 
mainly affected organs, leading to myocarditis, perivascular cuffing and interstitial 
pneumonia, due to an uncontrolled inflammatory response (Kulkarni et al., 1993; Shull 
et al., 1992). 
TGF-β2 null-mice suffer cardiac, lung, spinal column, carniofacial, limb, inner 
ear, eye, and urogenital defects; and the mutant is perinatally lethal (Sanford et al., 
1997). TGF-β3 null-mice die shortly after birth and present with a cleft palate. They 
suffer delayed lung maturation with alveolar hypoplasia, lack of alveolar septal 
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formation and diminished expression of surfactant protein C (SP-C) (Proetzel et al., 
1995).  
1.1.2 Additional signalling cascades active in the lung 
It is well known that components of the TGF-β signalling cascade are targets of 
other signalling pathways and vice versa. Indeed, this complex network of crosstalk 
modifies and amplifies the cell responses to TGF-β signalling, depending on the cell 
conditions and cell type (Derynck and Zhang, 2003; Massague, 2000). Moreover, TGF-
β ligands can signal through several Smad-independent pathways that can as well be 
regulated by other signalling pathways (Miyazawa et al., 2002) (Figure 1.3). 
1.1.2.1 Wnt pathway 
The Wnt signal transduction pathway has been identified as a key player in 
various developmental processes (Akiyama, 2000). The Wnt family comprises 19 
secreted glycoproteins, which bind to cell surface receptors called Frizzleds (Fz). The 
best characterised intracellular signalling pathway is the canonical β-catenin pathway 
(Pongracz and Stockley, 2006).  
Smad-dependent gene transcription can be modulated by the transcription factor 
β-catenin and vice versa (Lei et al., 2004; Nishita et al., 2000). On the other hand, 
Smad2 also regulates the β-catenin pathway (Nishita et al., 2000). Furthermore, both the 
Wnt and TGF-β pathways play a common role in the process of EMT in lung (Pongracz 
and Stockley, 2006), during embriogenesis and tumor metastasis (Nawshad et al., 2005) 
and heart development (Liebner et al., 2004). 
1.1.2.2 MAPK pathway: JNK, p38 and ERK MAP kinases 
The mitogen-activated protein kinases (MAPK) are a large group of proteins 
acting as signal transducing enzymes, since they facilitate extracellular signals to reach 
the cell surface to rapidly activate nuclear TF (Javelaud and Mauviel, 2005). Several 
extracellular stimuli can activate these serine-threonine kinases, which will 
subsequently phosphorylate nuclear kinases or TF (Mulder, 2000).  
The mammalian MAPKs have been classified into four groups according to the 
activating molecule: 1) the extracellular signal-regulated kinases (ERK1 and ERK2 or 
also designated as p44 and p42, respectively), 2) p38/MAPKs, 3) the stress-activated 
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protein kinases known as c-Jun N-terminal kinases (JNK1, JNK2 and JNK3), and 4) 
ERK5 (Chang and Karin, 2001).  
The MAPK activity is controlled by a sequential activation of several MAPK 
kinase kinase (MAPKKK or MEKK) and MAPK kinase (MAPKK, MEK or MKK) 
enzymes (Chang and Karin, 2001). The phosphorylated upstream kinase directs the 
activation of a certain downstream pathway. The ERK-mediated pathway, initiated by 
mitogens and several growth factors (GF), is involved in cell proliferation and 
differentiation and considered anti-apoptotic. The p38/MAPK and JNK-signalling 
pathways are activated by stress stimuli, such as, UV light, osmotic shock or 
inflammation, leading either to cell proliferation and differentiation or apoptosis, 
depending on the cell system (Javelaud and Mauviel, 2005).  
TGF-β can interact with all the pathways described above, except the ERK5 
pathway (Javelaud and Mauviel, 2005). Furthermore, the TGF-β-induced MAPK 
activation can follow either slow kinetics in a Smad-dependent pathway or rapid 
kinetics (5-15 min) in a Smad-independent pathway (Massague, 2000).  
The biochemical mechanism and the biological consequences of the crosstalk are 
currently poorly understood. Thus far, one well-characterised interaction is through the 
TGF-β-activated kinase 1 (TAK1), a MAPKKK family member, which is involved in 
the activation of both the JNK and p38 pathways (Shibuya et al., 1996; Zhou et al., 
1999). The MAPK pathways have been also implicated in the regulation of TGF-β 
responses. For instance, ERK phosphorylates the MH1 domain of Smad2 and the linker 
segments of Smad1, Smad2 and Smad3 (Derynck and Zhang, 2003; Kretzschmar et al., 
1999). Moreover, activation of MEKK1 can also result in Smad phosphorylation 
through the ERK and JNK pathways (Brown et al., 1999). Furthermore, JNK can 
directly phosphorylate Smad3 at its linker region (Billings et al., 2000; Mori et al., 
2004).  
1.1.2.3 NF-κB pathway 
Nuclear factor of κ-light polypeptide gene enhancer in B cells (NF-κB) is a 
generic name for a group of TF, which can induce or repress gene transcription, and are 
thus implicated in the regulation of cell proliferation, development, and apoptosis. NF-
κB plays a major role in the innate- and adaptive-immune responses (Perkins, 2007; 
Schmitz et al., 2004).  
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In the majority of cell types, NF-κB complexes are retained in the cytoplasmic 
compartment by the inhibitors of NF-κB (IκBs). The activation of the pathway requires 
IκB phosphorylation by IκB kinases (IKK) (Perkins, 2007). A large number of stimuli 
can lead to the NF-κB pathway initiation and most of them represent stressful or 
precarious conditions (Schmitz et al., 2004). 
TGF-β can stimulate the NF-κB pathway and vice versa. These two pathways act 
in an antagonistic manner in the regulation of immune-cell responses (Massague, 2000). 
For instance, through TAK1 activation, which then phosphorylates and activates the 
IKK, leading to the activation of the NF-κB pathway (Yamaguchi et al., 1999). 
Conversely, Smad7 levels can increase in response to TNF-α through the NF-κB 
pathway, inhibiting the Smad signalling pathway (Bitzer et al., 2000).  
1.1.2.4 PI3K/AKT pathway 
Phosphoinositide 3-kinases (PI3K) generate specific inositol lipids, which 
control cell growth, survival, differentiation, proliferation, and cytoskeletal changes. A 
well-characterised target of PI3K lipid products is the protein kinase AKT or also called 
protein kinase B (PKB) (Vanhaesebroeck and Alessi, 2000). AKT is a multifunctional 
cytoplasmic kinase, activated by various stimuli and has been implicated in cancer 
development (Barnett et al., 2005).  
Crosstalk between the PI3K/AKT and TGF-β pathways has also been reported. 
For instance, the upregulation of the type I collagen expression by TGF-β was proposed 
to be mediated by TGF-β-induced AKT phosphorylation in Swiss 3T3 cells (Runyan et 
al., 2004). It has been also suggested an essential role of the PI3 kinase in TGF-β-
mediated EMT and cell migration in NMuMG mammary epithelial cells (Bakin et al., 
2000). 
In conclusion, the interaction between downstream molecules in distinct 
signalling pathways may underlie diverse forms of integration and reciprocal regulation 
inside the cell (Massague and Chen, 2000). However, the implications of the Smad and 
other signalling molecule activation are still not well understood in vivo. 
 
1.2 LUNG ANATOMY, PHYSIOLOGY AND FUNCTION 
The principal function of the lung is to ensure efficient gas exchange, providing 
oxygen to the pulmonary and systemic blood, and removing the carbon dioxide 
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produced by cell respiration. The organ anatomy represents a well-optimised structure 
with a large exchange surface and a thin basement membrane, which enables rapid gas 
exchange by passive diffusion. The basement membrane is composed of both the 
endothelial and epithelial cell membranes fused together, minimizing the gas exchange 
surface to 0.2 µm, forming the alveolocapillary units. However, not only a thin 
basement membrane is needed for an optimal gas exchange, but also an optimal 
matching ratio between ventilation (V, air flow) and perfusion (Q, blood flow) is 
indispensable (Seeger et al., 1993; Von Euler, 1946). 
The pulmonary parenchyma represents about 85% of the total lung volume 
(respiratory bronchioles, alveolar ducts, alveolar sacs and alveolar capillary network), 
the conducting airways cover only about 6 to 10% (trachea, bronchi, bronchioles, 
terminal bronchioles) and the remaining part of the lung consists of nervous and 
vascular tissue (Gehr, 1984). The lung is divided into three functional regions: the 
ventilation (conducting and respiratory airways), the perfusion (bronchial and 
pulmonary blood supply), and the lymphatic areas. 
Several tissues are contained in the lung. The epithelial layer consists of at least 
13 cell types, 11 epithelial and 2 mesenchymal cell types. The interstitium contains 36% 
of the total number of cells, among them, the fibroblasts and myofibroblasts, cells that 
synthesise collagen and elastic fibers and the pericytes and SMC, which compose the 
capillaries and vessels. The endothelium contains about 30% of the total cell number, 
representing the largest capillary endothelial surface of the body and so, facilitating the 
gas exchange (Simionescu and Antohe, 2006). Moreover, cartilage synthesised by 
chondrocytes, is also present in the lung, though only surrounding the trachea and 
bronchi. At the alveoli, specialized cells are responsible for host defense, such as, the 
alveolar macrophages that accomplish phagocytosis (9% of total cell number); the 
plasma cells in charge of antibody production; granulocytes and also the mast cells, 
which store histamine and heparin (Corrigan and Kay, 1991).  
 
1.3 THE LUNG EPITHELIUM 
1.3.1 Cell types and function 
Epithelia are sheets of cells that are situated at the interface of two biologically 
distinct compartments. The epithelial layers form a semipermeable boundary and 
regulate the transport of ions and molecules between both compartments. Specially, the 
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pulmonary epithelium is necessary for an optimal gas exchange at the alveoli, and 
represents the first defense barrier between the host and the environment. The lung 
epithelium can be divided into proximal and distal, representing the respiratory 
epithelium and the gas exchange region, respectively. An intermediate area is found 
between them (Figure 1.4) (Breeze and Turk, 1984).  
The distal alveolar epithelium, included in the sacci and ducti alveolari, is 
responsible for the gas exchange. In the adult lung, it consists of two highly specialized 
alveolar epithelial cells (AEC): squamous type I (ATI) and cuboidal type II (ATII) cells 
(Wise, 2002). The ATI, or also called type I pneumocytes, are large and very thin (0.2 
µm in depth) cells. They cover over 95% of the alveolar surface (5,000 µm2) and 
represent the 8% of the total cell number in the lung. The passive gas diffusion takes 
place at the ATI and endothelial cell junctions (McElroy and Kasper, 2004). 
Additionally, they form a barrier against fluid leakage into the alveolar spaces, but 
allow a selective exchange of physiological solutes and water between blood and alveoli 
(Schneeberger and Lynch, 2004; Williams, 2003). Recent reports assume that the ATI 
cells retain the ability to trans-differentiate not only in vitro, but also in vivo (Flecknoe 
et al., 2002; Uhal, 1997). 
On the other hand, the ATII cells comprise only the remaining 5% of the 
respiratory lung surface area (180 µm2) and the 16% of the total pulmonary cells. These 
cells can be named granular AEC (as they contain lamellar bodies), large AEC (due to 
their big size), corner cells (they are normally found at the edges of the alveolar spaces) 
or type II pneumocytes. These cells synthesise, secrete and re-uptake surfactant proteins 
(SP), which are lipoprotein complexes of the lung innate immune system that reduce 
surface tension at the air-liquid interface and serve as pulmonary host defenses (Wright, 
2005). Four different surfactant proteins have been defined: SP-A, SP-B, SP-C and SP-
D, with SP-A and SP-D being specifically involved in the host defense (Mason et al., 
1998). The type II pneumocytes store the SP in so-called lamellar bodies, which are 
specialised secretory lysosomes (Gunther et al., 2001; Weaver et al., 2002). The ATII 
cells are multifunctional in that they regulate the alveolar lining fluid and its resolution 
and alter inflammation by GF and cytokine secretion (Manzer et al., 2006; Matthay et 
al., 2002). While the ATI cells are highly vulnerable to injury, the ATII cells are more 
resistant and act as progenitor cells for the re-epithelialisation process after epithelial 
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injury, by proliferation and trans-differentiation into ATI cells (Evans et al., 1975; Uhal, 
1997) (Figure 1.5.C). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Anatomy and histology of the lung. The lung contains several cell-types present at different 
regions. These areas are divided into a proximal region containing the trachea and bronchi (A), a medial 
region that possesses the bronchioli, internally covered with Clara cells and ciliated cells (B) and a gas-
exchange-region at a distal position (C). The epithelium varies from stratified (respiratory epithelium) to 
flattened cells and underlying it, other cell types are encounted (D). The cell type-specific markers for 
type I and II AEC, Clara, endothelial and smooth muscle cell (SMC) are indicated. Go: goblet cells, Ci: 
ciliated cells, Ba: basal cells, M: monocyte, AS: alveolar space, EC: endothelial cell, S: smooth muscle 
cell, 1: type I AEC and 2: type II AEC (modified after Breeze and Turk, 1984). 
 
At the intermediate region, where the bronchioli are situated, the respiratory 
epithelium is cuboidal with ciliated columnar and non-ciliated cells, the latter named 
Clara cells. The Clara cells are implicated in the production and secretion of the 
surfactant components, SP-A, SP-B and SP-D, as well as the Clara cell secretory protein 
(CCSP), also called CC-10, which is a key regulator of inflammation in the lung (Chang 
et al., 2000; Stripp et al., 2002). The Clara cells are considered to be the progenitor cells 
at the proximal airways and essential in detoxifying inhaled foreign material (Bishop, 
2004; Brody et al., 1987) (Figure 1.5.B). 
The epithelial layer lining in the proximal region consists of seven cell types: 
basal, goblet, ciliated, brush, serous, Clara, and neuroendocrine cells. These cells cover 
the tracheobronchial airways forming the so-called respiratory epithelium. Of note, the 
ciliated and goblet cells play a key role in duct clearing by mucus secretion and 
entrapment and transportation of inhaled airway insults (Rogers, 1994) (Figure 1.5.A).  
C 
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1.3.2 Cell type-specific markers  
A cell type-specific marker is a molecule present in a particular cell type, 
facilitating cell characterisation, identification, and perhaps cell isolation (Atkinson et 
al., 2001). Furthermore, biological markers or biomarkers are cell type-specific markers 
that help to diagnose a disease, as they are highly expressed or absent in pathological 
conditions compared to physiological levels (Hirsch et al., 2002; Tzortzaki et al., 2007). 
Some epithelial cell markers currently used in cell characterisation have been 
previously mentioned, for example the four surfactant proteins synthesised by ATII 
cells, and the CC-10 marker, unique to Clara cells. Some additional markers 
characterise type II pneumocytes. For instance, the type A γ-aminobutyric acid 
(GABAA) receptor π subunit (GABRP) (Chen et al., 2004) recently discovered with an 
as-yet undefined function in the lung or lysophosphatidylcholine acyltransferase 
(LPCAT), which is required for surfactant phospholipid biosynthesis as it remodels the 
phosphatidylcholine, an essential lipid for SP production (Chen et al., 2006). Moreover, 
SP synthesis is dependent on the combined actions of multiple TF. Among them, the 
thyroid transcription factor 1 (TTF-1/Nkx2.1), which is a common positive regulator of 
their promoter activity (Bohinski et al., 1994) and the forkhead box P2 (Foxp2) that acts 
as a transcriptional repressor for murine CC-10 promoter, regulating proximal versus 
distal epithelial cell differentiation (Shu et al., 2001). 
Podoplanin (T1α) was the first molecular marker identified for ATI cells 
(Williams et al., 1996). T1α is essential for optimal alveolar sacculation (Millien et al., 
2006). Moreover, the water channel aquaporin (AQP) 5, key for fluid permeability 
between the airspace and the capillaries, also specifically identifies this cell type in the 
lung (Borok et al., 1998; Nielsen et al., 1997; Verkman et al., 2000). 
The type I and II pneumocytes also share the expression of some markers 
(McElroy and Kasper, 2004), including the Na+/K+ transporting ATPase α and β 1 
polypeptides (Atp1α1 and Atp1β1, respectively) present at the basolateral surface of the 
AEC (Machado-Aranda et al., 2005; Matthay et al., 2002). Additionally, the β subunit 
of the epithelial sodium channel (β-ENaC) is present in both cell types (Jernigan and 
Drummond, 2005; Matthay et al., 2002). 
Other pulmonary cell types express different specific markers. Among them, the 
collagen Iα1, synthesised and secreted by fibroblasts and myofibroblasts, forms part of 
the ECM (Oda et al., 1988). The contractile proteins α-smooth muscle actin (α-SMA), 
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calponin, and smooth muscle-myosin heavy chain are mainly expressed by vascular 
SMC (Shanahan and Weissberg, 1998). The platelet-endothelial-cell adhesion molecule-
1 (PECAM-1) is a marker restricted to platelets and endothelial cells (Ilan and Madri, 
2003).  
Following injury, the quantity of the newly synthesised cell marker proteins 
differ from physiological levels. Thus, these changes in expression levels may facilitate 
early diagnosis of pulmonary disease and thus reduce the associated mortality, by 
allowing characterisation of novel molecular pathways that could be targeted in 
therapeutic interventions (McElroy and Kasper, 2004). 
1.3.3 Lung epithelium-related diseases 
Epithelial barrier disruption requires a rapid and efficient re-epithelialisation of 
the denuded basement membrane. However, the epithelial repair process may be 
disturbed, leading to aberrant alveolar epithelial cell populations (e.g., cells co-
expressing epithelial and mesenchymal markers) (Willis et al., 2005) and thus to a 
deregulation of cytokine secretion (increase levels of TGF-β, the central regulator of 
-PF-) (Selman et al., 2001), abnormal pulmonary surfactant production, and alveolar 
collapse (Taskar et al., 1997). Epithelial injury is evident in many lung diseases, 
including bronchopulmonary dysplasia (BPD) (Jobe and Bancalari, 2001), acute lung 
injury (ALI) or acute respiratory distress syndrome (ARDS) (Geiser, 2003b; Martin et 
al., 2005), cystic fibrosis (Matthay et al., 2002) and idiopathic pulmonary fibrosis (IPF) 
(Geiser, 2003a; Selman et al., 2001). Abnormal airway remodelling and partial lost of 
epithelium is also observed in chronic obstractive pulmonary disease (COPD) (Puchelle 
et al., 2006).  
Different types of insults provoke repeated microscopic injuries at the 
pulmonary epithelial layer and it is thought that a combination of events trigger the 
disease. Among the known epithelial damage insults are tobacco smoke (Van Winkle et 
al., 2001; Wistuba et al., 2002), pollutants, bacteria, viruses (Puchelle et al., 2006), and 
gastroesophageal reflux (Selman and Pardo, 2006). 
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1.4 TGF-β AND EPITHELIAL LUNG DISEASES 
1.4.1 Expression and role of TGF-β in the lung 
The TGF-β cytokines are part of a regulatory molecule network that control lung 
homeostasis and homeodynamics, required during lung branching and lung tissue 
repair. The three TGF-β ligand-coding genes are highly expressed in the mouse during 
lung morphogenesis. TGF-β1 is found as early as day 11 in the cytoplasm of stromal 
and epithelial cells of the primordial ducts and play a major role in lung branching 
(Schmid et al., 1991). The constitutive activation of TGF-β1 in a transgenic mouse 
model led to lung morphogenesis arrest and inhibition of epithelial cell differentiation, 
where neither pro-SP-C nor CC-10 were detected. On the contrary, type I collagen was 
present in the terminal airways and the distribution of α-SMA was markedly altered 
(Serra et al., 1994; Zhou et al., 1996). TGF-β1 also inhibited surfactant synthesis and 
epithelial cell maturation in human lung explants (Beers et al., 1998; Zhou et al., 1996). 
In the human developing lung, all three TGF-β isoforms are highly expressed. They 
play a decisive role in branching morphogenesis and epithelial cell differentiation with 
the concomitant surfactant maturation (Bartram and Speer, 2004; Chapman, 2004). 
All three TGF-β isoforms are also found in the adult murine lung, primarily 
expressed at the bronchial epithelium. There is considerable controversy regarding the 
TGF-β ligand localization in other cell types, as there are studies reporting expression 
either in the AEC, in the vascular endothelium, or mesenchymal cells (Coker et al., 
1996; Pelton et al., 1991). In line with the mouse TGF-β ligand expression pattern, the 
TGF-β ligands in the adult human lung are primarily expressed in the bronchial 
epithelial cells (BEC) (Magnan et al., 1994), alveolar macrophages, other inflammatory 
cells, vascular and airway SMC, and mesenchymal cells (Coker et al., 1996; Magnan et 
al., 1994). 
1.4.2 TGF-β-related lung disorders 
A common characteristic of many diseases is an inflammatory process related to 
tissue injury, followed by a phase of repair. Elevated concentrations of active TGF-β1 
are found in patients, which suffer inflammatory lung diseases (Table 1) (Bartram and 
Speer, 2004). Moreover, in different organs, including the liver and kidney, high levels 
of this isoform have been also detected (Branton and Kopp, 1999; Sime and O'Reilly, 
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2001). This results in an enhanced matrix deposition and a downregulation of the 
inflammatory response after injury. These imbalanced levels of the cytokine, due to an 
exaggerated repair process, may generate fibrotic lesions in the organs (Bartram and 
Speer, 2004; Letterio and Roberts, 1996). TGF-β1 is the predominant TGF-β isoform in 
disease conditions, although the upregulation of the other two isoforms has also been 
described (Bartram and Speer, 2004). 
 
 Table 1: TGF-β1-related lung diseases 
Disease Source 
Chronic lung disease of prematurity (Kotecha et al., 1996) 
Idiopathic pulmonary fibrosis (IPF) (Khalil et al., 1991) 
Giant-cell interstitial pneumonia (Corrin et al., 1994) 
Occupational diseases 
(silicosis, asbestosis, pneumoconiosis) 
(Jagirdar et al., 1997) 
(Vanhee et al., 1994) 
Sarcoidosis (Limper et al., 1994) 
Lymphangioleiomyomatosis (LAM) (Evans et al., 2004) 
Cystic fibrosis (Wojnarowski et al., 1999) 
Chronic obstructive lung disease (COPD) (de Boer et al., 1998) 
Asthma (Aubert et al., 1994) 
Transplantation-related diseases 
(bronchiolitis obliterans) 
(Magnan et al., 1996) 
 
Table 1: TGF-β1-related lung diseases. The main respiratory diseases associated with an imbalanced 
TGF-β1 expression are listed (modified after Bartram and Speer, 2004). 
 
The consequences of abnormally high concentrations of TGF-β1 in the lung 
have been studied in a variety of models. The mouse model of bleomycin-induced lung 
fibrosis perfectly mimicks the upregulation of the three different isoforms (Santana et 
al., 1995). Furthermore, TGF-β1 overexpression in transgenic mice using tissue-specific 
promoters has provided various model systems to study the effects of an increased TGF-
β1 activity in the intact organism (Bottinger and Kopp, 1998; Zhou et al., 1996). 
Additionally, TGF-β1 overexpression, assessed by intratracheal instillation of 
replication-deficient adenovirus vectors into the rat lung, demonstrated that only the 
active form of the cytokine resulted in pathological conditions. A severe interstitial and 
pleural fibrosis resulted, characterised by extensive deposition of the ECM proteins, 
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such as collagen, fibronectin, and elastin, and by the emergence of cells with a 
myofibroblast phenotype (Sime et al., 1997).  
1.4.3  Idiopathic Pulmonary Fibrosis (IPF) 
Idiopathic pulmonary fibrosis (IPF) is a progressive and devastating disease with 
unknown aetiology. The disease normally develops from the middle age onwards, with 
men twice as likely as women to be affected from IPF. Currently there is no available 
treatment, and after diagnosis the median survival is between three and five years 
(Selman and Pardo, 2002). The long-prevailing hypothesis of inflammation being the 
main trigger of the disease is been currently debated, since the response to steroids is 
usually poor in IPF, and the use of other immunosupressors has largely failed to 
increase the survival rate (Geiser, 2003a). Furthermore, studies on transgenic animal 
models indicate that the inflammatory response and the fibrotic response can be 
dissociated (Munger et al., 1999).  
It has been recently proposed that IPF may result from a sequential epithelial 
injury, leading to the loss of the epithelial cell integrity, which is a consistent finding in 
IPF (Coalson, 1982; Kasper and Haroske, 1996). The injurious agent will affect both the 
increase in AEC apoptosis (Maeyama et al., 2001) and the inhibition of AEC 
proliferation, trans-differentiation and migration (Kasper and Haroske, 1996). All 
together, this would impair the normal re-epithelialisation of the denuded area, leading 
to an abnormal wound healing (Selman and Pardo, 2002) (Figure 1.5.A).  
The remaining AEC after epithelial injury have been shown to produce a number 
of soluble factors, like TGF-β1 (Khalil et al., 1991), TNF-α (Kapanci et al., 1995) or 
platelet-derived growth factor (PDGF) (Antoniades et al., 1990), that are known to 
promote fibroblast activation. The active fibroblasts, the so-called myofibroblasts, 
migrate to the denuded area, where they undergo abnormal proliferation, leading to the 
formation of the so-called fibroblast foci (Figure 1.5.B). These myofibroblasts 
synthesise large amounts of ECM molecules and a variety of cytokines, including the 
profibrotic TGF-β1 (Serini and Gabbiani, 1999). Increased amounts of TGF-β1 mRNA 
and protein have been encountered. The abnormal deposition of ECM molecules results 
in the destruction of the alveolocapillary units, leading to impairment of normal lung 
function. An inefficient re-epithelialisation occurs over the fibroblastic foci; however, 
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the distance between the AEC and endothelial cells is too large, impeding gas-exchange 
(Figure 1.5.B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Hypothetical model of impaired wound healing for IPF. A) Constant and multiple 
microinjuries damage the AEC (top left) and the remaining AEC synthesise several GF, including TGF-
β1 (bottom left). The denuded area is covered by migrating fibroblasts, where they proliferate forming 
fibroblast foci (bottom right). The myofibroblasts synthesise angiogenic factors to induce 
neovascularisation. The production of angiotensin II promotes AEC re-epithealization; however, the gas-
exchange process is impaired by the fibroblast foci (top right) (after Selman M. et al., 2001). B) 
Haematoxylin and eosin staining of a fibroblast foci in IPF lung (after Geiser T., 2003b).   
   
The fact that the myofibroblasts are the principal cell type participating in the 
pathogenesis of IPF is well described, as the progression of the IPF is associated with 
fibroblastic foci in the lung (King et al., 2001). The source for these activated 
spindle-shape cells, which express various mesenchymal makers, is currently under 
discussion. Three hypotheses have been proposed thus far to explain their origin: 
- The first postulates the activation and proliferation of local fibroblasts, upon 
stimulation (Phan, 2002). TGF-β1 promotes differentiation of cultured isolated 
primary rat fibroblasts into myofibroblasts through the Smad3 signalling 
pathway (Hu et al., 2003).  
- The second hypothesis claims that an engraftment of bone marrow-derived 
progenitor cells occurs. These cells then differentiate into myofibroblasts in 
the respiratory tract (Epperly et al., 2003; Hashimoto et al., 2004).  
- The recently postulated hypothesis is related to EMT, where epithelial cells are 
considered to be the source of the mesenchymal cells by TGF-β1 induction 
(Zavadil and Bottinger, 2005).  
The EMT process is a complex and extreme manifestation of epithelial cell 
plasticity, in which the polarized epithelial cells convert to fibroblastoid cells capable of 
locomotion (Thiery, 2002). The required cellular changes are the loss of the epithelial 
cell-cell and cell-matrix adhesion contacts and activation of de novo synthesis of ECM 
A B 
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molecules. At the transcriptional level, a simultaneous repression of epithelial markers 
(occludin and E-cadherin) and an upregulation of mesenchymal markers (α-SMA and 
vimentin) are observed (Ikenouchi et al., 2003).  
The transmembrane proteins, occludin and ZO-1, are responsible for the tight 
junction maintenance and the E-cadherin extracellular domains to sustain adherens 
junctions, which maintain the epithelial cell polarity by interacting intracellularly with 
the actin cytoskeleton via α- and β-catenins (Zavadil and Bottinger, 2005). When the 
disassembly of cell-cell junctions including tight, gap and adherens junctions, and 
desmosomes occurs, integrity of the epithelial layer is lost. Simultaneously, the 
trans-differentiated epithelial cells synthesise vimentin intermediate filaments, which 
form the motile elements of the cellular architecture, along with the actin-containing 
microfilaments (Helfand et al., 2004). The fibroblast specific protein 1 (FSP1), also 
known as S100A4, has been described as a marker for differentiated fibroblasts (Strutz 
et al., 1995).  
Many GF like EGF, hepatocyte growth factor (HGF), fibroblast growth factor 
(FGF) and TGF-β; endothelin-1 (ET-1) and members of the Wnt signalling pathway 
promote EMT (Jain et al., 2007; Radisky, 2005). Interestingly, both the EMT process 
and fibrogenesis are common in epithelial-enriched organs, like the lung and kidney 
(Willis et al., 2006). Specifically, the TGF-β1 ligand promotes, through the Smad-
dependent pathway (principally by the Smad3) (Roberts et al., 2006), other TF 
including Slug, Snail, and β-catenin, which are related to the epithelial cell 
trans-differentiation into mesenchymal cells (Kalluri and Neilson, 2003; Masszi et al., 
2004). TGF-β1-induced EMT has been demonstrated in the human epithelial A549 cell-
line (Kasai et al., 2005), on rat lung epithelial-T-antigen negative (RLE-6TN) and 
isolated primary ATII cells (Willis et al., 2005). Additionally, colocalisation of 
mesenchymal and epithelial markers in the same cell was demonstrated in IPF lung 
sections (Kim et al., 2006; Willis et al., 2005).  
  
1.5 STUDIES ON LUNG EPITHELIUM 
Research on the pulmonary epithelial layer has been accomplished by either 
isolation of various primary cell types, following microdissection, or 
fluorescence-activated cell sorting (FACS), thus avoiding tissue homogenates, which 
have the disadvantage of masking genetic deviations or expression changes of an 
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individual cell type by the surrounding cell bulk (Curran et al., 2000). However, the 
enzymatic digestion methods to obtain single cell suspensions for both FACS and short-
term cell cultures may induce cellular changes as they are subjected to different 
environmental factors. 
Several enhanced methods for isolating and culturing primary adult rat and 
mouse cells and fetal human type II pneumocytes are currently available (Wang et al., 
2007). Their gene and protein expression under different culture conditions and their 
cell response upon stimulation is also well characterised. However, it has been 
demonstrated that isolated primary ATII cells change their phenotype upon culture 
(Gonzalez et al., 2005). They gradually trans-differentiate into ATI-like cells, as they 
loose their lamellar inclusion bodies, become flat and change their gene expression 
profile (Chen et al., 2004; Paine and Simon, 1996). This trans-differentiation occurs 
between day 3 and 5 after isolation, and cell type-specific markers from both the ATII 
and the ATI cell types are localized simultaneously, indicating the existence of a 
possible intermediate cell type (Bhaskaran et al., 2007; Chen et al., 2004; Danto et al., 
1995). Interestingly, a trans-differentiation of ATII cells into mesenchymal cells has 
also been demonstrated in vitro and in vivo (Willis et al., 2005). Moreover, the 
trans-differentiation process depends, to a great extent, on the presence or absence of 
matrix on which the ATII cells are plated (Gonzales et al., 2002). When they are 
cultured on uncoated dishes (on a plastic surface), their phenotype is rapidly altered 
(Chen et al., 2004; Paine and Simon, 1996). The matrices can be composed of different 
molecules (fibronectin or laminin-5 alone), where the ATII cells change their phenotype 
(Guo et al., 2001; Olsen et al., 2005), on a mixture of fibronectin/collagen/laminin-5 or 
on Matrigel along with some GF, where the type II phenotype is preserved longer 
(Olsen et al., 2005; Wang et al., 2007). Additionally, the EMT process can differ 
depending on the ECM composition onto which ATII cells are attached (Zeisberg et al., 
2001).  
Recently, laser capture microdissection (LCM) has improved the current 
knowledge on cell gene and protein expression, as LCM enables fine microdissection of 
a specific pool of cells (Betsuyaku et al., 2001; Fink et al., 2006). However, the 
microdissection machinery is extremely expensive and the technique demands manual 
dexterity, and is prone to some operator bias. Furthermore, the mode of tissue section 
preparation may also modify the results (Curran et al., 2000; Kim et al., 2003) and a 
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high probability of RNA degradation by endogenous RNases has been reported (Kohda 
et al., 2000).   
Differentiated ATII cell-lines are not currently available. Nevertheless, several 
cell-lines with an epithelial origin have been established. For instance, the NCI-H441 
cell-line derived from a human pulmonary papillary adenocarcinoma highly expresses 
SP-A (O'Reilly et al., 1988). The A549 cell-line, which is frequently used in studies on 
the lung epithelium, was explanted from a human lung carcinomatous tissue, although 
any SP expression is absent (Mason and Williams, 1980). In addition, cell-lines with a 
rodent origin, such as, murine lung epithelial (MLE) 12 (Alejandre-Alcazar et al., 2007) 
and RLE-6TN (Willis et al., 2005) have been usually utilised. However, the cell-lines 
are limited in that they are immortalised and in many cases transfected and transformed, 
processes that completely change their gene expression patterns (Malkinson et al., 
1997).  
Many different screening approaches have been performed thus far in order to 
ascertain novel biomarkers for the various pulmonary diseases. For instance, some using 
cell-lines and arrays (Koike et al., 2004), studying the trans-differentiation of ATII cells 
into ATI in vitro by microarrays (Chen et al., 2004) or also comparing freshly isolated 
ATI, ATII and cultured ATII using microarray analysis (Gonzalez et al., 2005). Thus, 
the currently used cell type specific markers have been developed in vitro and thus far, a 
comprehensive analysis of the epithelial gene transcription in vivo has not been yet 
attempted. 
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2 AIM OF THE STUDY 
  
While primary AEC culture has increased our knowledge of AEC gene 
expression in vitro, a comprehensive analysis of epithelial cell gene transcription in vivo 
has not yet been attempted. The aim of the study was to profile the epithelial cell gene 
expression in the murine lung in vivo by developing a new technique, in which RNA 
from the lung epithelium would be isolated directly from the mouse lung, avoiding cell 
plating.  
Furthermore, the influence on the epithelial gene expression profile of TGF-β1, a 
cytokine related to many different lung diseases, was studied by direct administration of 
the ligand into the murine lung. 
By combination of these two optimised approaches, the study of the TGF-β1 
influence on the epithelial gene expression in vivo was assessed.   
 
In summary, the specific aims of this work are as follows: 
 
1. The establishment of a novel method to isolate RNA directly from epithelial 
cells in the murine lung, avoiding cell plating. This has been termed “epithelial 
lavage”. 
2. Characterisation of epithelial gene expression in vivo. 
3. Comparison of RNA expression between the epithelial lavage samples, primary 
isolated ATII cells, and epithelial cell-lines.  
4. Orotracheal administration of the TGF-β1 cytokine. 
5. Analysis of the TGF-β1-induced signal transduction of both Smad-dependent 
and -indendent pathways. 
6. Analysis of TGF-β1 early-responsive genes in the epithelial layer. 
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3 MATERIALS AND METHODS 
 
3.1 MATERIALS 
3.1.1 General chemicals 
Table 2: General laboratory chemicals 
Compounds Company 
β-mercaptoethanol Sigma-Aldrich 
3MM Whatman paper 
Schleicher and 
Schnell 
100 bp DNA ladder Promega 
Agarose Invitrogen 
Ammonium Persulfate (APS) Promega 
Biotin-16-2´-deoxyuridine 5´-triphosphate (dUTP) Roche 
Bradford reagent Bio-Rad 
Complete™ (Protease inhibitor cocktail tablets) Roche 
Dispase BD Biosciences 
Dithiothreitol (DTT) Promega 
Dual colour precision protein standards Bio-Rad 
ECL Western blotting detection reagents Pierce 
Eythelene diamino tetra acetic acid (EDTA) Promega 
Ethidium bromide Roth 
GEArray Q Kit SuperArray 
Glycerol Promega 
Glycogen Sigma-Aldrich 
GoTaq® Flexi DNA Polymerase Promega 
Isoflurane Baxter  
Herring Sperm DNA Promega 
Isotonic sodium chloride solution DeltaSelect 
Ketavet® (Ketamine) Pharmacia 
Methanol Fluka 
M-MLV Reverse Transcriptase Promega 
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Mouse Genomic DNA Promega 
Mouse Universal Reference Total RNA Clontech 
Laboratories 
Nitro-cellulose membrane Bio-Rad 
Non-fat dry milk powder Roth 
Nonidet P-40 Sigma-Aldrich 
Oligo(dT)15 Primer Promega 
PCR Nucleotide Mix Promega 
Platinum SYBR Green qPCR 
SuperMix UDG 
Invitrogen 
Phosphate-buffered saline (PBS) PAA 
RNase-Free Dnase set Qiagen 
RNase inhibitor Promega 
RNaseZAP Sigma-Aldrich 
Rompun® (Xylazine) Bayer Vital 
Rotiphorese® gel 30 Roth 
Roti-Quick-Kit (Solution 1, 2 and 3) Roth 
Sodium deoxycholate Sigma-Aldrich 
Sodium dodecyl sulfate (SDS) Promega 
Sodium ortho vanadate Sigma-Aldrich 
TEMED Bio-Rad 
TGF-β1 R&D Systems 
Toluidine Blue O Sigma-Aldrich 
Tris Roth 
Tween-20 Sigma-Aldrich 
3.1.2 Cell culture reagents 
Table 3: Cell culture reagents 
Compounds Company 
β-estradiol Sigma 
Dulbecco’s modified Eagle medium (DMEM) Gibco 
Fetal calf serum (FCS) PAA 
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HEPES PAA 
Hydrocortisone Sigma 
Insulin/Transferrin/NaSelenit Gibco 
Trypsin-EDTA PAA 
3.1.3 Primers 
The primers were designed using the Primer3 Input Internet programme 
(frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi), assuring specificity by the 
nucleotide-nucleotide BLAST programme (http://www.ncbi.nlm.nih.gov/BLAST). 
Primers were synthesised by Qiagen, Germany, at the synthesis scale of 0.05 µmol. The 
primer sequences are listed in the Appendix (Table A.17). 
3.1.4 Antibodies 
Table 4: Primary antibodies 
Catalogue No. Description Supplier 
A 5228 α-smooth muscle actin Sigma 
9272 AKT Cell Signaling 
SC-601 CDK4 (H-22) Santa Cruz 
Biothechnology 
9212 p38 Cell Signaling 
9102 p44/42 MAPK Cell Signaling 
4058 Phospho-AKT (Ser473) (193H12) 
Rabbit mAb 
Cell Signaling 
9211 Phospho-p38 (Thr180/Tyr182) Cell Signaling 
9106 Phospho-p44/42 MAPK 
(Thr202/Tyr204) (E10) mouse mAb 
Cell Signaling 
SC-8979 PAI-1 (H-135) Santa Cruz 
Biotechnology 
3101 Phospho-Smad2 (Ser465/467) Cell Signaling 
9514 Phospho-Smad3 (Ser423/425) / 
phospho-Smad1 (463/465)  
Cell Signaling 
610843 Total Smad 2/3 BD Biosciences 
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61-7300 ZO-1 Zymed 
 
Table 5: Secondary Antibodies 
Name Description Supplier 
Mouse horse-radish peroxidase Anti-mouse IgG (H + L) Cell Signaling 
Rabbit horse-radish peroxidase Anti-rabbit IgG (H + L) Cell Signaling 
 
3.2 METHODS 
 
3.2.1 Mammalian cell culture 
All cells were maintained at 37 °C in a humidified incubator in 5% (v/v) CO2 
and 95% (v/v) air. All cells were grown in cell culture flasks. Storage of cells was done 
by harvesting cells and adding 1 ml of freezing medium (10% (v/v) DMSO in fetal calf 
serum (FCS)). The cells were transferred to a cryovial, placed on ice for 1 h and 
transferred to –80 °C for 1 day prior to storage in liquid nitrogen. To thaw cells, the 
cryovial was removed from liquid nitrogen and placed at 37 °C for 10 min The cells 
were transferred to 10 ml of pre-warmed fresh medium followed by a light 
centrifugation before being re-plated onto cell culture dishes in fresh medium.  
3.2.1.1 Cell isolation 
Primary alveolar type II (ATII) cells were isolated from adult female C57BL/6N 
mice (18-20 g) as previously described (Corti et al., 1996). Briefly, mice were sacrificed 
by intraperitoneal injection of a mixture of ketamine and xylazine (1:1:2 - 
Ketavet®:Rompun®:saline in a final volume of 200 µl). The thoracic cavity was opened 
carefully to avoid puncturing the lung. Trachea was exposed by a midline neck incision 
and a catheter was inserted and ligated. The abdomen was opened, the renal artery was 
separated and pneumothorax was drawn. Afterwards, lungs were perfused with saline 
and lavaged. Next, the proteolytic enzyme dispase (1.2 ml) was introduced to dissociate 
the pulmonary epithelial cells from their basement membrane, followed by agarose 
instillation (0.4 ml), maintained in liquid form at 55 °C. Agarose solution was allowed 
to solidify for 2 min inside the lungs and the respiratory organ was then separated from 
the thorax and incubated in 1 ml dispase solution for 45 min at room temperature.  
MATERIALS AND METHODS 
 
40 
 
After dispase disaggregation, the purification method, based on the differential 
adherence to IgG-coated Petri dishes of immune, contaminating cells, was performed. 
The ATII cell preparations used were > 95% viable, as determined by trypan blue dye 
exclusion (cells were incubated for 2 min with the dye, blue-stained cells were 
considered non-viable) and 92–96% pure, as determined by lamellar body staining with 
Nile Red. Briefly, the Nile Red staining was performed as follows: 20 µl of cell 
suspension in 500 µl DMEM were combined with 1:20 Nile Red solution, vortexed and 
incubated for 5 min at room temperature. Stained cells were counted under UV-light. 
The ATII pneumocytes were then plated either on uncoated or fibronectin-coated dishes 
(100 µg/ml) in conditioned medium. 
3.2.1.2 Cell culture  
For sub-culturing, cells were washed twice with ice-cold 1× PBS and 2-3 ml of 
trypsin-EDTA was added and incubated at 37 °C until the cells were well dispersed. To 
these cells, 7 ml of fresh complete growth medium was added and the cells were 
aspirated gently by pipetting and finally aliquoted into new culture vessels. The murine 
lung epithelial cell-line MLE 12 was cultured in HITES medium supplemented with 2% 
FCS, according to the recommendations of the American Type Culture Collection 
(www.atcc.org). The ATII cells were cultured in DMEM with 10% FCS. 
3.2.2 Molecular biology techniques 
3.2.2.1 Epithelial lavage extraction 
Adult male C57BL/6N mice were sacrificed by an intraperitoneal injection of 
ketamine/xylazine (1:1:2 - Ketavet®:Rompun®:saline in a final volume of 200 µl) and 
tracheostomised. The lungs were then lavaged twice with saline. This fraction was 
centrifuged for 5 min, at 13,000 r.p.m. and snap frozen. Subsequently, 600 µl of a 1:20 
guanidinium isothiocyanate Roti-Quick1 dilution (Roti-Quick-Kit, Roth) was applied 
and retained for 30 seconds inside the lung. Immediately after, 600 µl of saline were 
introduced into the lung, withdrawn, and added to the previous extraction. The final 
volume of ~ 1100 µl was then added onto 200 µl of undiluted Roti-Quick1 solution and 
snaped frozen. 
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3.2.2.2 RNA isolation from cultured cells 
Total RNA from MLE12 cells and freshly isolated and subsequently cultured 
ATII cells was isolated using the QIAshredder columns (Qiagen) to disrupt the DNA 
and then followed the Qiagen RNeasy MiniKit protocol. 
3.2.2.3 RNA isolation from lung homogenates 
Total RNA was isolated from unfixed lung tissue after epithelial lavage 
extraction. The right lobe was ground to powder under liquid nitrogen with a mortar and 
pestle. Guanidinium isothiocyanate (Roti-Quick1) was added to the tissue to isolate 
RNA, which was separated from the sheared DNA and proteins by adding 
phenol/chloroform (Roti-Quick2), and precipitated overnight with isopropanol 
(Roti-Quick3). Further steps were performed according to the manufacturer’s protocol.  
3.2.2.4 RNA isolation from epithelial lavage samples 
Total RNA isolation from the epithelial lavage samples was performed with the 
Roti-Quick-Kit as described above. In order to improve the RNA precipitation, and 
therefore, the final RNA concentration, glycogen (1 µl/700 µl per extraction) was added 
as a co-precipitant for the overnight precipitation with isopropanol.  
3.2.2.5 Reverse transcription (RT) reaction 
A reverse transcription (RT) reaction was performed with the Sensiscript RT Kit 
(Qiagen) suitable for low quantities of RNA. According to the manufacture’s protocol, 
50 ng of high quality total RNA and diethylpyrocarbonate (DEPC)-treated water to a 
final volume of 13 µl were combined and heated to 65 °C for 5 min The reaction was 
snap-chilled on ice to allow annealing of Oligo(dT)15 to the poly A tail of the mRNA. 
Meanwhile, a master-mix of the other reagents was prepared, in a total volume of 7 µl, 
as follows: 
 
Table 6: Master-mix preparation for RT reactions 
RT reaction component Volume 
10× buffer 2 µl 
dNTP Mix (5 mM each dNTP) 2 µl 
Oligo(dT)15 1 µl (10 units) 
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Rnase inhibitor 1 µl 
Sensiscript Reverse Transcriptase 1 µl 
 
Later, master-mix was added to the reaction tube and transferred to a PCR 
machine programmed for maintaining 37 °C for 60 min  
3.2.2.6 Polymerase chain reaction (PCR) 
3.2.2.6.1 Semiquantitative PCR 
All semiquantitative PCRs were performed using the PCR kit from Promega 
(Madison, WI, USA), in a total volume of 25 µl as follows: 
 
Table 7: Master-mix preparation for semiquantitative PCR reactions 
Components Volume/Amount 
Template cDNA 10 ng (1µl) 
Forward primer 10 pmole (0.5µl) 
Reverse primer 10 pmole (0.5µl) 
40 mM dNTP mix 0.5 µl 
5× PCR buffer 5 µl 
25 mM MgCl2 2 µl 
Go Taq Polymerase 0.25 µl 
Double-distilled water to 25 µL 15.25 µl 
 
The tubes were then transferred to a PCR machine (Peltier Thermal Cycler-200, 
MJ Research, Ramsey, MN, USA) set for 20 cycles in the case of housekeeping genes 
and 35 cycles for the rest of genes, following the next steps: 
Table 8: Programme for semiquantitative PCR reactions 
PCR step Temperature Duration 
First denaturation 95 °C 2 min 
Second denaturation 95 °C 45 s 
Annealing 60 °C 45 s 
Extension 72 °C 1 min 
Final extension 72 °C 10 min 
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Primer efficiency and optimal annealing temperature test were also performed 
by following a gradient PCR programme in DYAD machine (MJ Research, Ramsey, 
MN, USA): 
 
Table 9: Programme for gradient PCR reactions 
PCR step Temperature Duration 
First denaturation 95 °C 5 min 
Second denaturation 95 °C 45 s 
Annealing 58-62 °C 30 s 
Extension 72 °C 1 min 
Final extension 72 °C 10 min 
3.2.2.6.2 Quatitative PCR (qPCR) 
All quantitative PCRs were performed using the Platinum® SYBR® Green qPCR 
SuperMix-UDG (Invitrogen, Carlsbad, CA, USA), in a total volume of 25 µl as follows: 
 
Table 10: Master-mix preparation for quantitative PCR reactions 
Components Volume/Amount 
Template cDNA 5 ng (1 µl) 
Forward primer 10 pmole (0.5 µl) 
Reverse primer 10 pmole (0.5 µl) 
50 mM MgCl2 4.0 mM (0.5 µl) 
2× PCR buffer 13 µl 
 
The plate was then transferred to the 7500 Fast Real-Time PCR System (Applied 
Biosystems, Foster City, CA, USA) set for 45 cycles. The gene expression was analysed 
by the 7500 Fast System Software. The programme set was as follows: 
 
Table 11: Programme for quantitative PCR reactions 
PCR step Temperature Duration 
Activation of polymerase enzyme 50 °C 2 min 
First denaturation 95 °C 5 min 
Second denaturation 95 °C 5 s 
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Annealing 59 °C 5 s 
Extension 72 °C 30 s 
Dissociation step 1 95 °C 15 s 
Dissociation step 2 60 °C 1 min 
Dissociation step 3 95 °C 15 s 
Dissociation step 4 60 °C 15 s 
 
The specific amplification of the PCR products was confirmed by melting curve 
analysis and gel electrophoresis. Additionally, Ct values were calculated as follows: 
Ct = Ct reference gene (hprt) – Ct target gene; denoting Ct the cycle number where the 
fluorescence value is above the determined threshold and each unit of Ct represents a 
2-fold change in the target gene mRNA expression (Kwapiszewska et al., 2005). Ct 
values were plotted in Box and Whisker graphs, in which the box denotes the 
interquartile range (25-75%) and the horizontal line indicates the median. The whiskers 
or error bars indicate the 95% confidence interval and possible “outliers” of Ct values. 
Ct mean values were also blotted as mean ±SD in column graphs. 
3.2.2.7 DNA agarose gel electrophoresis 
The DNA sample along with the loading buffer (0.01% (m/v) Bromophenol 
blue; 40% (v/v) glycerol; 1× TAE buffer) was loaded onto either a 1% (m/v) agarose gel 
(semiquantitative RT-PCR) or 2% (m/v) agarose gel (quantitative RT-PCR). 
Electrophoresis was performed for 30-45 min with 5 V/cm (Bio-Rad, USA), where the 
negatively charged DNA migrates from the cathode to the anode. To visualise DNA, the 
gel was treated with ethidium bromide (0.5 µg/ml). The size of the DNA fragments was 
determined by a DNA molecular weight standard. 
3.2.2.8 Oligo microarray 
The RNA amount used to perform the gene expression analysis of the TGF-β 
treated lungs on the Oligo GEArray® Mouse TGF-β/BMP Signalling Pathway 
Microarray (OMM-035, SuperArray®, Frederick, MD, USA) was 3 µg. The RNA 
served as template to synthesise a biotin-labeled cDNA probe. Two different 
master-mixes were made as follows: 
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Table 12: Labelling master-mix for cDNA probe synthesis 
Components Volume 
5× GEA labelling Buffer (BN) 8 µl 
Biotin-16-dUTP (1µM) 4 µl 
RNase inhibitor (40 U/µl) 2 µl 
Reverse transcriptase (200 U/µl) 0.5 µl 
RNase-free water 5.5 µl 
 
 
Table 13: Annelling master-mix for cDNA probe synthesis 
Components Volume 
Total RNA (3 µg) x µl 
GEAprimer Mix (Buffer A) 3 µl 
RNase-free water 10-x µl 
 
 The annelling master-mix was placed in a PCR machine (Peltier Thermal 
Cycler-200, MJ Research, Ramsey, MN, USA) and warmed to 70 °C for 3 min to 
denature secondary structures in the RNA strands, and then cooled to 42 °C for 2 min. 
Both master-mixes were combined and the labeling reaction was performed at 42 °C for 
90 min  
In the meanwhile, the GEArray® membrane was pre-hybridisated by adding 
2 ml of de-ionized H2O and 2 ml of GEAhyb® hybridisation solution containing 
heat-denatured herring sperm DNA (100 µg DNA/ml). The GEArray® membrane was 
placed for 1 h into an oven (60 °C) with a continuous agitation (5 r.p.m.). 
 In order to stop the labelling reaction, 2 µl of 10× stop solution (Buffer C) was 
added. Immediately after, the sample was denatured, when 2 µl of the pre-warmed 10× 
denaturing solution (Buffer D) were added and incubated for 20 min at 68 °C. 
Afterwards, 25 µl of 2× pre-warmed neutralisation solution (Buffer E) were combined 
and incubated at 68 °C for 10 min 
 During this time, the pre-hybridisation solution was discarded from the 
membrane and the cDNA probe (50 µl) was mixed with another 1 ml of GEAhyb® 
hybridisation solution and was added onto the membrane. The hybridisation to the 
membrane was performed overnight in an oven with continuous agitation at 60 °C. 
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On the following day, the membrane was washed (2× 10 min) with 
solution 1 (2× SSC and 1% SDS) and again (2× 10 min) with solution 2 (0.1× SSC and 
0.5% SDS) at 60 °C. Pre-warmed GEA blocking solution Q was added to the membrane 
and incubated for 40 min in a lab rotator. Afterwards, incubation with alkaline 
phosphate-conjugated streptavidin (diluted at 1:8000 in 1× washing buffer F) for 10 min 
with gentle shaking was performed, followed by three washing steps with 1× washing 
buffer F. Afterwards, the membrane was rinsed twice with 1× AP-assay buffer G, 
incubated with 1 ml CDP-Star chemiluminescent substrate, and signal was finally 
detected by chemiluminescence. Data analysis was performed on web-based GEArray® 
Analysis Suite software. Intensity levels on the blank samples were substracted from 
gene spots and data was normalized to the gapdh gene expression. 
A short overview of the GEArray procedure is provided in the Appendix 
(Figure A.1). The array layout table containing the short and long name, and location of 
the murine genes on the microarray is attached in the Appendix (Table A.18).  
3.2.3 Immunological methods 
3.2.3.1 Immunohistochemistry 
Three-µm paraffin sections mounted on poly-L-lysine-coated slides were 
dewaxed by immersion in xylene (3× 10 min) and rehydrated by immersion in ethanol 
(5 min, 2× 100%, 2× 95%, and 2× 70% v/v) followed by a 1× phosphate-buffered saline 
wash (PBS). After antigen retrieval in 1× citrate buffer (in a pressure cooker for 20 min 
followed by a 10 min-warming step), endogenous peroxidase activity was blocked with 
3% (v/v) H2O2 for 20 min. The blocking reagent was applied for 10 min to prevent non-
specific binding. Sections were incubated with the relevant primary antibody overnight 
at 4 °C. On the following day, tissue slides were incubated with the relevant 
biotinylated secondary antibodies for 10 min, followed by streptavidin-conjugated 
enzyme for another 10 min, and chromogen substrate incubation for 10 min (Zymed; 
Histostain Plus Kit). All the steps described above were preceded by washing 2× 5 min 
with 1× PBS. Finally, sections were counterstained with haematoxylin for 8 min and 
washed under running tap water for 10 min. Sections were mounted by mounting 
medium and examined under a bright field microscope (Leica Mikroscopie und Systeme 
GmbH). 
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3.2.3.2 Western blotting 
i) Protein isolation from lung tissue 
The lung tissue was ground to powder under liquid nitrogen and lysed in RIPA 
lysis buffer (1× PBS without calcium and magnesium, 0.5% (m/v) sodium 
deoxycholate, 1% (m/v) SDS, 1% (v/v) Nonidet P-40) containing a mixture of protease 
and phosphatase inhibitors. The lysates were vortexed in a period of 30 min every 5 min 
and centrifuged at 13,000 r.p.m. for 15 min. The supernatant protein concentration was 
measured and stored at -80 °C. 
 
ii) Protein separation by poly acrylamide gel electrophoresis (PAGE) 
The separating gel mixture (Table 15) was poured between two glass plates and 
allowed to polymerise. The stacking gel mixture (Table 16) was poured on the top of 
the separating gel and the comb was inserted in the gel to form the wells. The gel was 
run in 1× Laemmli-loading buffer (25 mM Tris-Cl pH 8.3, 0.2 M glycine and 0.1% 
(v/v) SDS) until the desired distance had been reached. 
 
iii) Immunoblot 
After gel electrophoresis, proteins were transferred to a nitrocellulose membrane 
using a Bio-Rad transfer chamber containing transfer buffer (24 mM Tris base, 193 mM 
glycine, 10% (v/v) methanol), at room temperature for 1 h at 100 V.  Blots were 
incubated for 1 h in blocking buffer (5% (m/v) non-fat dry milk powder in PBS 
containing 0.1% (v/v) Tween-20) at room temperature. Incubation with the respective 
primary antibodies (1 µg/ml) was in blocking buffer for 1 h at room temperature or 
overnight at 4 °C in the case of anti-phospho antibodies. After 3× 5 min wash with 
washing buffer (1× PBS, 0.1% (v/v) Tween-20), blots were incubated with the 
respective HRP-labeled secondary antibodies (0.3 µg/ml) at room temperature for 40 
min After 4× 10 min washing with washing buffer, the blots were developed by 
enhanced chemoluminescence and visualised with Hyperfilm ECL (Kodak). To 
re-probe with another antibody, the blots were stripped with stripping buffer (0.063 M 
Tris-Cl pH 6.8, 2% (m/v) SDS, 0.7% β-mercaptoethanol) at 52 °C for 30 min, and then 
probed as described above. 
 
 
MATERIALS AND METHODS 
 
48 
 
Table 14: Composition of 10% resolving gels (40 ml) 
Component Volume 
Distilled water 15.9 ml 
30% acrylamide mix 13.3 ml 
1.5 M Tris-Cl (pH 8.8) 10 ml 
10% (m/v) SDS 400 µl 
10% (m/v) APS 400 µl 
TEMED 16 µl 
 
Table 15: Composition of  5% stacking gels (20 ml) 
Component Volume 
Distilled water 13.6 ml 
30% acrylamide mix 3.32 ml 
1 M Tris-Cl (pH 6.8) 2.52 ml 
10% (m/v) SDS 200 µl 
10% (m/v) APS 200 µl 
TEMED 20 µl 
3.2.4 Animal handling 
Six to eight week-old male C57BL/6N mice with body weight of 20 to 22 g were 
purchased from Charles River Laboratories (Sulzfeld, Germany). Animals were housed 
in humidity- and temperature-controlled rooms on 12:12 hs light-dark cycle with free 
access to rodent chow and tap water. All experiments were conducted according to the 
institutional guidelines that comply with national and international regulations.   
3.2.4.1 Instillation of substances into the murine lung 
Liquid instillation and nebulised aerosols are the predominant delivery methods 
for pulmonary drug administration in experimental setups. The different solutions used 
were: for optimisation, 1% (m/v) Toluidine Blue O in saline solution, which eases the 
comparison of the deposition yield between five different delivery procedures; and for 
TGF-β application, the recombinant protein diluted in saline. 
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3.2.4.1.1 Orotracheal administration (OT) 
The mice were lightly anesthetised with halothane breathing. Afterwards, the 
animals were placed under the binocular microscope suspended by the superior cranial 
incisors. The mouth was wide opened, the tongue was held with blunt forcers (to block 
the swallow reflex), and the nasal orifices pinched close with a pair of curved forceps, 
forcing breath through the mouth. In this way, the visualization of the oropharyngeal 
cavity and pharynx was possible. Tongue restraint was maintained until at least two 
breaths were completed and then the mice were allowed to recover by themselves. Of 
note, all animals completely recovered after this procedure. 
3.2.4.1.2 Intranasal administration (IN) 
Mice were lightly anesthetized with ketamine/xylazine 
(1:1:2-Ketavet®:Rompun®:saline in a final volume of 200 µl) intraperitoneally (i.p.) and 
settled in a recumbent position or with an angle of 45° to ease normal breathing. Small 
drops of 1% (m/v) Toluidine Blue O solution were given to the nose every 15 s, to a 
final volume of 40 µl.  
3.2.4.1.3 Intratracheal administration (IT) 
The animals were deeply anesthetized i.p. with ketamine/xylazine solution 
(1:1:2-Ketavet®:Rompun®:saline in a final volume of 200 µl) and placed on a heating 
pad to maintain body temperature in the physiological range. The trachea was exposed 
by a midline neck incision and a canula, connected to a needle, was inserted. The 1% 
(m/v) Toluidine Blue O solution was slowly administrated. When necessary, animals 
were artificially ventilated after this procedure and the survival rate was 100%. 
3.2.4.1.4 Microspray (MS) 
Mice were lightly anesthetised i.p. with ketamine/xylazine solution 
(1:1:2 -Ketavet®:Rompun®:saline in a final volume of 200 µl). The mouth was opened, 
a canula was intubated into the trachea under microscopic guidance. The final volume 
of Toluidine Blue O solution was instilled with the help of the Microsprayer™ (Penn-
Century Inc., PA, USA).  
3.2.4.1.5 Nebulisation (NB) 
Animals were anesthetized intraperitoneally with ketamine/xylazine 
(1:1:2 -Ketavet®:Rompun®:saline in a final volume of 200 µl) and placed on a heating 
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pad to maintain body temperature at physiological range. Mice were tracheostomized 
and artificially ventilated with room air with the use of an Aeroneb® Professional 
Nebulizer System (Aerogen) respirator. This ultrasonic nebulizer was positioned in the 
respiratory limb of the ventilator tubing. The Aeroneb® nebulizer produced an aerosol 
with a mass median aerodynamic diameter (MMAD) of < 3.0 µm and a geometric 
standard deviation (GSD) ≤ 2.2. 
3.2.5 Statistical analysis 
The Ct mean values from the indicated groups were compared using the 
two-tailed Student’s t-test. A level of p<0.05 was considered statistically significant. 
Standard deviations were calculated as SD= √ (SD1) 2 + (SD2)2.  
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4 RESULTS 
 
4.1 OPTIMISATION OF LOCAL DELIVERY TO THE LUNG 
Five different techniques for administering liquid substances into the lung have 
been described (Sakagami, 2006; Sweeney and Brain, 1991). These are the intratracheal 
(IT), intranasal (IN), microspray (MS), orotracheal (OT) and the nebulisation (NB) 
methods. Direct inhalation approaches are not commonly performed, as they require 
specialised equipment and consume large amounts of the particulate insult, and the 
exact dose inhaled cannot be possible estimated (Hanson et al., 1985). For this reason, 
many investigators choose to mix the molecule of interest with a carrier liquid such as 
saline, to prevent the particles from agglomeration (Driscoll et al., 2000; Schermuly et 
al., 1997). For repetitive dosing, the liquid must be carefully instilled in order to prevent 
airway destruction, disturbance of normal breathing and induction of coughing, which 
would lead to a rapid lung liquid clearance. The first four procedures mentioned above 
are commonly utilised in pharmacodynamic investigations, although they are reported 
to be nonphysiological, as a large volume is administered into the lung (Driscoll et al., 
2000).  
The deposition efficacy was compared for the five techniques using a 1% (m/v) 
Toluidine Blue O solution for a quick and easy visual assessment (Lakatos et al., 2006; 
Visweswaraiah et al., 2002) (Figure 4.1). A detailed description of each method is given 
in the Materials and Methods section. After ink administration, mice were immediately 
sacrificed and lungs were explanted.  
 
1) The classical intratracheal (IT) method is regularly utilised in animal 
laboratories, because the dose delivery can easily be measured and it 
minimises the risks for laboratory workers, compared to inhalation methods 
(Driscoll et al., 2000). Two different instillation volumes were used in this 
study, 100 and 200 µl. When the lower volume was utilised, only a small area 
was covered by the ink. However, the 200 µl volume was sufficient to cover 
around 85% of the lung external surface. 
2) The intranasal (IN) method is a non-invasive method and has often been used 
for induction of viral infections and allergic sensitization (Cates et al., 2004; 
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Leong et al., 1998; Lundstrom, 2001). The total ink volume utilised was 40 µl. 
Firstly, the animal was positioned horizontally. The deposition rate yielded 
very low (approximately 2%), as it was only visualised in the trachea and 
principal bronchi. Then the animal was re-positioned at 45°. This facilitated 
the uptake of the entire volume, as the nose ceased to produce bubbles. 
Around 15% of the lung surface was covered by the ink. However, a large 
deposition of ink to the stomach was observed.  
 
3) The microspray (MS) technique was reported to dispense uniformly and  
dispersed to the discrete pulmonary airway via bronchoscopy (Hoover et al., 
1993; Sakagami, 2006). For the MS method, two different volumes were 
employed, 100 and 200 µl. Both demonstrated effective deposition covering at 
least ~70% of the lung surface.  
 
4) The orotracheal (OT), also called transtracheal or oropharyngeal aspiration, 
has been recently described (Lakatos et al., 2006; Rao et al., 2003). Through 
this method, 80% of the lung surface was covered, when 80 µl of the 
1% Toluidine Blue O solution was utilised. An additional experiment was 
performed using several ink volumes: 80, 100, 120, and 140 µl (Figure 4.2). 
The higher the volume instilled, the better the deposition. However, 80 µl was 
considered sufficient to reach the majority of the lung surface.  
 
5) The nebulisation method (NB) employed a nebuliser system, which converts 
liquid into an aerosol (Leong et al., 1998; Schermuly et al., 1997). The NB 
method was not efficient, as the lung did not contained much 1% Toluidine 
Blue O solution, except for a small area on the lung surface and in the trachea 
(5%), although high volumes were utilised (100 and 200 µl). Interestingly, the 
ink was visualized in the nebuliser system, leading to the conclusion that the 
losts of nebulised substances is very high by this method.  
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Figure 4.1: Optimisation of local delivery to the murine lung. Five different instillation approaches 
(intratracheal -200 µl-, intranasal -40 µl-, microspray -100 µl-, orotracheal -80 µl-, and nebulisation -100 
µl-) to administer substances into the lung were compared (n = 2 per condition). Mice were instilled with 
different volumes of 1% Toluidine Blue O solution, depending on the technique used. The deposition rate 
in the lung surface of 1% Toluidine Blue O solution was observed A) in situ and B) in the lung explants 
(ventral and dorsal views). The top left panel depicts a mouse lung that was not treated but inflated with 
air (control lung).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Overview of the OT method. A) The OT method was performed as follows: mice were 
lightly anesthetised, then suspended by the cranial incisors under the binocular microscope, the nose was 
pinched closed by forceps, mouth was opened, and the desired volume was pipetted into of the mouth. B) 
Several volumes of 1% Toluidine Blue O solution (80, 100, 120 and 140 µl) were orotrachally 
administered into the lung (n = 4 per condition). C) Deposition of ink could be observed in the digestive 
system. 
A 
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100 µl 140 µl 
B 
C 
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Intranasal Microspray 
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Only three methods were efficient enough to cover more than 70% of the lung 
surface. These were the IT, MS and OT techniques (Figure 4.1). For further 
experiments, the OT aspiration was chosen, as it yielded the best deposition (applied 
volume/lung covered area), relatively small amounts of ink leaked into the stomach, due 
to indirect flux, and for its rapidness and easiness (Figure 4.2). In addition, it was the 
only approach in which light anesthesia was used, and there was no perianesthetic death 
associated with this procedure.  
 
4.2 TGF-β1 ADMINISTRATION 
After choosing the OT method as the most efficient approach for administration 
of substances to the distal lung, due to its rapidity, simplicity, and use of light 
anaesthesia, the TGF-β1 recombinant ligand was applied. Furthermore, the OT 
technique was previously reported to be useful for the delivery of antigens, infectious 
agents, vectors and silica particles, thereby inducing PF (Lakatos et al., 2006; Singh et 
al., 2004).  
Our first aim was to analyse whether the ligand reached the lung, and once there, 
was still active; thus phosphorylation of the TGF-β1 downstream molecules was 
assessed by Western blotting. Several ligand concentrations (0.25, 0.5, 2.25, and 2.5 
ng/µl) diluted in saline (total volume 80 µl) were instilled into the murine lung and 
secondly, different retention times of the recombinant cytokine (30 min, 2h, and 6 h) 
within the lung were analysed. At the same time, in order to distinguish between the 
TGF-β1 effect itself and the stress produced in the lung during the instillation 
procedure, non-treated (naïve) and saline-treated (80 µl of NaCl) mice were included in 
the study.  
Furthermore, the following aim was to ascertain which genes were activated 
after OT ligand delivery in the lung homogenates, as the TGF-β1 early-responsive genes 
have not been yet described in vivo. Using the same ligand concentrations and retention 
times as mentioned above and later isolating RNA from the lung homogenates, the 
induction or repression in target gene transcription, was assessed by semi-quantitative, 
quantitative RT-PCR, and oligo microarrays. Moreover, the identification of the 
cell-type responsive to TGF-β1 was determined by immunohistochemistry.  
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4.2.1 Orotracheally-instilled TGF-β1 activates the Smad-dependent 
pathway  
Mice were instilled with several TGF-β1 concentrations (0.25, 0.5, 2.25, and 2.5 
ng/µl) and sacrificed at different times (30 min, 2h, and 6 h). Then proteins were 
extracted and blotted against phospho-Smad2, phospho-Smad3, phospho-ERK1/2, 
phospho-p38, and phospho-AKT, in order to investigate which pathway 
(Smad-dependent or -independent) was activated by TGF-β1. 
The results depicted in Figure 4.3 are a representation of untreated, saline-treated 
and mice treated with several TGF-β1 concentrations (n = 2-3 per condition). As 
evident from Figure 4.3.A, the recombinant ligand reached the respiratory organ and 
was still able to activate intracellular signalling pathways, as assessed by 
phosphorylation of the downstream molecules. Interestingly, only the R-Smad proteins 
were phosphorylated after TGF-β1 administration. Phospho-Smad2 and phospho-
Smad3 activation was independent of the TGF-β1 concentration, as the phosphorylation 
signal was observed after administration of low (0.25 ng/µl) or high (2.5 ng/µl) 
concentrations of ligand. Phosphorylation of AKT was observed in every mouse 
submitted to the OT instillation, indicating that the AKT activation was not a TGF-β1-
specific response. Nevertheless, the phosphorylation state is stronger upon TGF-β1 
presence in the longest studied period (6 h) and high ligand concentrations. This 
phosphorylation may be induced by both the stress produced in the animal during the 
OT instillation and the TGF-β1 cytokine. Phosphorylation on other MAPK downstream 
molecules was not observed (p38 or ERK1/2) (Figure 4.3.A).  
Moreover, in order to compare the same ligand concentration and its effect after 
different time points, the lung protein content was extracted 30 min or 6 h after TGF-β1 
ligand was instilled (2.5 ng/µl) (Figure 4.3.B). As earlier assessed by Western blotting, 
only the Smad pathway was activated, but AKT phosphorylation was as well observed. 
Neither p38 nor ERK1/2 molecules were phosphorylated (Figure 4.3.B).  
Taken together, Figures 4.3.A. and 4.3.B. indicate that phosphorylation of 
Smad2 occurred solely after TGF-β1 instillation. However, the phospho-Smad3 signal 
was observed on saline-treated and naïve murine lungs, as well suggesting that Smad3 
activation also occurs at basal state in the lung, and this activation was enhanced when 
TGF-β1 was instilled (Figure 4.3.B). In addition, TGF-β1-mediated Smad3 
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phosphorylation kinetics demonstrated an early response (after 30 min) and a late 
response (after 6 h) (Figure 4.3.B).   
In conclusion, only the Smad-dependent pathway was specifically activated by 
TGF-β1, as no specific phosphorylation on the related Smad-independent downstream 
signalling molecules was observed (MAPK pathways). However, the phosphorylation 
of AKT, due to stress conditions produced during the treatment, may lead to additional 
intracellular responses. The concomitant activation of both R-Smad and AKT occurred 
under low and high concentrations of the recombinant cytokine, and at early and late 
time points after ligand delivery.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: TGF-β1-induced phosphorylation of the downstream signalling molecules. A) Protein 
expression levels after administration of several TGF-β1 concentrations (0.25, 0.5, 2.25, and 2.5 ng/µl) 
and B) cytokine retention time-points within the lung (30 min and 6 h., 2.5 ng/µl TGF-β1) were compared 
to control mice (naïve) and saline-treated mice by Western blotting. Membranes were incubated with anti-
phospho-Smad2, -Smad3, -AKT, -p38, and -ERK1/ERK2 and pan antibodies anti-AKT, -Smad2/3, -p38 
and -ERK1/ERK2. CDK4 served as internal loading control. Arrows indicate standard protein molecular 
weight (n = 6).  
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4.2.2 TGF-β1-induced gene transcription 
In order to study the transcriptional induction of TGF-β1 on the respiratory 
organ, total RNA from lung homogenates orotrachally instilled with various 
concentrations (0.25, 0.5, 2.25, and 2.5 ng/µl) and retention time-points (2h, and 6 h) of 
ligand, was isolated and reversed transcribed (n = 2-5 treated mice per condition). Next, 
semi-quantitative RT-PCR for well-characterised TGF-β1 target genes was performed. 
These genes were the connective tissue growth factor (ctgf), growth arrest and DNA-
damage-inducible 45 β gene (gadd45b) (Takekawa et al., 2002), the junB oncogene 
(junb), plasminogen activator inhibitor-1 (serpine1) and Smad7 (smad7). As is evident 
in Figure 4.4, the ctgf, gadd45b, junb, serpine1, and smad7 genes were upregulated in 
the presence of the TGF-β1 ligand. The ctgf and serpine1 genes exhibited the major 
response to TGF-β1, compared to their basal expression in the naïve and saline-treated 
mice. The gene expression changes were neither dependant on the duration or on the 
concentration of the stimulus. However, the gene expression levels were not elevated in 
some mice, meaning that some animals did not react to TGF-β1. This may be explained 
by the fact that some animal movement during the OT application could have occurred, 
leading to improper deposition of the applied liquid, or to the intervariability found 
between individuals of the same species. 
 In conclusion, a change in the gene expression profile induced by TGF-β1 in the 
murine lung was confirmed. The TGF-β1 target genes ctgf, gadd45b, junb, serpine1, 
and smad7 were rapidly (after 2 h) upregulated and low ligand concentrations (0.25 
ng/µl) were efficient enough to enhance their transcription. 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: TGF-β1-induced upregulation of early-responsive target genes. Four different TGF-β1 
concentrations (0.25, 0.5, 2.25, and 2.5 ng/µl) were instilled into the murine lung. Mice were sacrificed 2 
h (0.25 and 2.25 ng/µl) or 6 h (0.5 and 2.5 ng/µl) after instillation. Total RNA was isolated from lung 
homogenates, along with control (naïve) and saline-treated murine lungs. Upregulation of TGF-β1 
responsive genes was assessed by semi-quantitative RT-PCR. GAPDH served as internal loading control. 
Negative controls contained H2O as template for the RT and PCR steps (n = 6).  
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Additionally, murine oligo GEArray® membranes were utilised in order to 
further investigate the TGF-β1-regulated transcriptional genes within the TGF-β 
superfamily members. For these reason, total RNA was isolated from untreated mice 
and mice OT instilled with a concentration of 2.5 ng/µl of TGF-β1. Afterwards, the 
amplified, biotin-labelled antisense RNA was hybridised onto a TGF-β/BMP signalling 
pathway microarray and signal was visualised by chemiluminiscence (Figure 4.5.A and 
B). The TGF-β1-induced gene transcription or repression is represented in Figure 4.5.C. 
The spotted genes have been listed in the Appendix section, along with the short and 
long names (Table A.18).   
Interestingly, many genes were repressed when TGF-β1 was instilled (Figure 
4.5.B and C). Among them, many members of the BMP family, several BMP ligands 
(e.g. Bmp4), the acvrl1 receptor, and the inhibitory smad6. In addition, downregulated 
were members of the collagen family, the TβRIII (tgfbr3) or also called betaglycan, and 
the distal-less homebox 2 (dlx2). From the Id family, solely the idb2 member was 
significantly expressed to a lesser extent when the ligand was added. On the contrary, 
some genes were upregulated after TGF-β1 administration, like serpine1, which 
upregulation was already observed in the semi-quantitative RT-PCR analysis; the 
type III TGF-β receptor known as BAMBI, several members of the growth 
differentiation factor (GDF) family, IL-6, the TGF-β induced (tgfbi) gene, and the BMP 
inhibitor Noggin, which binds to the BMP-4 ligand (Figure 4.5). However, 
transcriptional regulation of the R-Smads in the lungs was not observable upon TGF-β1 
instillation, but on protein level by activation via phosphorylation (Figure 4.3).  
In order to confirm some of the results obtained by the semi-quantitative 
RT-PCR and the microarray technique, quantitative RT-PCR was performed on the 
same homogenate samples acquired from untreated or TGF-β1-treated mice (2.5 ng/µl 
for 6 h) on 5 animals per condition. For instance, the expression level of a member of 
the collagen family, collagen Iα1, exhibited a faint downregulation after TGF-β1 
application, following the same pattern as in the microarray analysis. The 
TGF-β1-induced downregulation of the idb2 gene observed by the microarray (highest 
repression by TGF-β1) approach was corroborated by quantitative RT-PCR.  
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Figure 4.5: Gene transcription regulation by TGF-β1 in the murine lung (microarrays): The gene 
expression pattern on A) naïve and B) TGF-β1-treated lungs (2.5 ng/µl, for 6 h) was compared by the 
GEArray® TGF-β superfamily gene array. Total RNA was isolated and hybridised onto the specific 
membrane. C) The short name of the genes and their corresponding position on the membrane, the 
regulation factor and error standard deviations are depicted. Comparison between the arrays (TGF-β1 vs. 
naïve) was performed by the on-line GEArray® Analysis Suite Software. Intensity of spots was 
normalized to gapdh gene expression and background from blank samples was substracted. The 
penultimate row contains the negative controls and the bottom row is spotted with housekeeping genes (n 
= 3). 
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The serpine1 gene expression, already demonstrated to be upregulated by 
semi-quantitative RT-PCR and microarray techniques (highest induction by TGF-β1), 
was again significantly upregulated in the murine lungs after cytokine administration. 
Furthermore, the upregulation of the junb gene transcription by semi-quantitative 
RT-PCR could not be confirmed by microarray analysis, where the TGF-β1 induction 
was not observed. Neither the upregulation of the ctgf gene as it was not spotted in the 
utilised microarray. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Regulation of gene transcription by TGF-β1 in the murine lung (quantitative RT-PCR). 
Expression of TGF-β1-regulated genes was analysed by real-time RT-PCR, using RNA from lung 
homogenates from untreated and TGF-β1-treated mice (2.5 ng/µl, for 6 h). *: p≤0.05 for the comparison 
between the naïve and TGF-β1-treated fractions (n = 2). 
 
In conclusion, low concentrations of instilled TGF-β1 rapidly induced gene 
repression of many members of the BMP family; inhibition that was expected as the 
TGF-β and BMP signalling pathways have antagonistic effects on the cell. Furthermore, 
inhibition of idb2 transcription was observed under TGF-β1 stimulation, in contrast to 
the previously reported fast induction upon BMP ligand binding (Miyazono and 
Miyazawa, 2002). Regarding the consistent and increased serpine1 expression levels, 
three different techniques demonstrated that this gene is highly and rapidly upregulated 
upon TGF-β1 stimulation in the lung in vivo.  
 
4.2.3 Immunohistochemistry on saline and TGF-β1-treated murine 
lungs 
The TGF-β1 effect on the lung was also analysed by immunohistochemistry, so 
that, the cells responding to the ligand could also be visualised. Two molecules were 
chosen as representing downstream molecules: PAI-1, which upregulation was 
∆
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determined previously on RNA level (Figure 4.6) and phospho-Smad2, as immediate 
responsive molecule after TGF-β1 administration (Figure 4.3).  
Saline- and TGF-β1-treated lungs (0.5 ng/µl) were fixed 6 h after ligand 
administration and stained for PAI-1 (Figure 4.7.A) and phospho-Smad2 (Figure 4.7.B). 
The bronchoalveolar cells (BEC) and the alveolar epithelial cells (AEC) were the only 
immunoreactive cells for both target proteins. PAI-1 staining was evident in the 
cytoplasmic compartment of these cells, whereas the phospho-Smad2 nuclear staining 
was indicative of its translocation into the nucleus upon TGF-β1 stimulation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Bronchial and alveolar epithelial cells respond to TGF-β1 instillation. Immunological 
representative fields of A) PAI-1 and B) phospho-Smad2 are illustrated. 0.5 ng/µl of recombinant protein 
diluted in saline were instilled into the murine lungs; control lungs received only saline (80 µl final 
volume). The organs were fixed and explanted after 6 h (n = 3). 
 
In conclusion, TGF-β1 application through the OT method was efficient, in that 
the ligand could reach the lung and activate gene transcription and phosphorylation of 
the downstream signalling molecules. The signal transduction was active at low and 
high ligand concentrations and at early and late time points. The TGF-β1-responsive 
cells were situated at the epithelial layer; specifically two cell types were reactive: the 
BEC and AEC localised the activated TGF-β1 downstream signalling molecules.  
 
4.3 EPITHELIAL LAVAGE 
The cells found to be responsive to TGF-β1 were present in the epithelial layer 
(both the BEC and the AEC). Due to the necessity to find novel pulmonary epithelial 
cell-specific markers expressed in vivo, a novel approach was developed to isolate the 
RNA contained in the epithelial cells of the murine lung. The advantage of this method 
10x 
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would be to avoid cell plating, process that potentiates the expression of different 
markers differently than in situ (Chen et al., 2004; Paine and Simon, 1996), and thus 
studying the gene expression profile in the in vivo situation. In this way, modification of 
gene expression profiles reported to occur during cell culture conditions would be 
obviated (Bhaskaran et al., 2007; Chen et al., 2004). The technique developed was 
performed similarly to a bronchoalveolar lavage (BAL) (Connett, 2000); and therefore, 
was named “epithelial lavage” (EL).  
Briefly, the EL proceeded as follows: mice were sacrificed and tracheostomised. 
Lungs were lavaged twice with saline and an appropriate dilution of guanidinium 
isothiocyanate (GI) was then instilled into the organ. The solution was withdrawn from 
the lung and finally RNA was isolated using the phenol/chloroform precipitation 
method (Huang et al., 1995). An epithelial RNA fraction with minimal contamination of 
adjacent cells was successfully recovered, as assessed by cell-specific marker gene 
expression (semi- and quantitative RT-PCR).  
4.3.1 Epithelial lavage: optimisation of the guanidinium 
isothiocyanate concentration 
In order to isolate RNA from epithelial cells lining the respiratory surface of the 
lung, a solution containing GI was used, as this chemical disrupts the cells, denatures 
proteins, and suppresses RNase activity. This solution is normally employed for RNA 
isolation from tissues and cells.  
Before GI application, two consecutive saline lavages (500 µl each) were 
performed to eliminate the maximal amount of lining fluid and non-epithelial cells 
covering the epithelium, like immune and dead cells (Connett, 2000). An appropriate 
dilution of the GI solution became necessary, as an undiluted solution led to the 
immediate rupture of the lung. Therefore, a series of dilutions, including 1:20 dilution 
of GI and 1:40 dilution were instilled (600 µl) (n = 4 mice per group). The volume was 
then recovered and maintained on ice, together with 200 µl of undiluted GI, to 
accelerate cell disruption and prevent RNase activation. Afterwards, a supplementary 
saline fraction was instilled to facilitate the recovery of additional disrupted cells. This 
fraction was extracted from the lung and added to the previously withdrawn solution. 
Total RNA was isolated from the extracted volume by the EL method, the BAL fraction 
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and the remaining lung homogenates, using the phenol/chlorofom method, as described 
in the Materials and Methods section (Huang et al., 1995).  
Cell type-specific marker expression in the EL fractions was analysed by 
semi-quantitative RT-PCR, including epithelial and non-epithelial markers. As evident 
from Figure 4.8, the Clara cell marker CC-10 (scgb1a1), and the AEC marker ATPase, 
Na+/K+ transporting beta 1 polypeptide (atp1b1) and the ATII cell marker pro-surfactant 
protein B (sftpb) were amplified in the 1:20 dilution fractions. This amplification 
indicated that RNA was isolated from both the proximal and the distal epithelium, 
respectively. The non-epithelial markers analysed were characteristic for SMC and 
endothelial cells, so as to exclude any contamination from adjacent cells and thus ensure 
the extraction of RNA solely from epithelial cells. The platelet-endothelial-cell adhesion 
molecule 1 (pecam1), restricted to platelets and endothelial cells, was not amplified. 
Additionally, the commonly used marker for SMC, α-smooth muscle actin (acta2) was 
also not detected. The 1:40 dilution only disrupted the proximal epithelium, evident by 
the CC-10 marker amplification.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: Optimisation of the required dilution of GI solution for the EL technique. Two different 
dilutions of GI were applied to four mice each, 1:20 and 1:40. Amplification of epithelial and non-
epithelial cell type-specific markers was assessed by semi-quantitative RT-PCR. GAPDH served as 
internal loading control. +PCR: positive control for the PCR step containing mouse genomic DNA. -RT: 
negative control for the RT step lacking RNA template. 
 
Taken together, it could be concluded that a diluted solution of GI was necessary 
in order to recover RNA from the pulmonary epithelial layer. The 1:20 dilution of GI 
was the optimal concentration to isolate a pure epithelial fraction from both the distal 
and the proximal areas of the lung, without any RNA contamination from adjacent cells. 
The 1:40 dilution was not sufficient to disrupt the epithelial cells situated in the gas-
exchange region.  
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4.3.2 Epithelial lavage: retention time optimisation 
After optimising the required dilution of GI, different retention times of the 1:20 
diluted GI within the lung were investigated, as the final RNA concentration and 
possible contamination of adjacent cells might vary. The times selected were the 
following: introducing the solution and subtracting it immediately (in and out, ~ 1 s) 
and after 10, 30, and 60 s. As observed in Figure 4.8, the 30 s time point fraction 
yielded the highest RNA concentration and exhibited epithelial marker specificity, as 
assessed by semi-quantitative RT-PCR. Solely in the representative fraction of 30 s, the 
AEC gene marker, atp1b1, was amplified, as well as, the Clara cell marker, scgb1a1. 
The specific markers of other cell-types, PECAM-1 and α-SMA, were not amplified. A 
longer retention time (1 min) did not yield a higher total RNA concentration. Therefore, 
in order to prevent possible contaminations and to achieve the highest RNA 
concentration, the 30 s time point was utilised for further analysis. 
 
 
 
 
 
 
 
 
 
Figure 4.9: Optimisation of the required retention time of GI within the lung for the EL technique. 
The EL fractions obtained by the 1:20 dilution of GI at different retention time points (1 s, 10 s, 30 s and 
60 s) were analysed for cell type-specific markers by semi-quantitative RT-PCR. GAPDH served as 
internal loading control. -RT: negative control for the RT step lacking RNA template (n = 2). 
 
4.3.3 Reproducibility of the epithelial lavage technique 
The next question to be answered was if the novel experimental approach could 
be repetitively performed without variations on the marker expression profile. In this 
respect, the EL was conducted using the 1:20 dilution of GI maintained for 30 s within 
the lung (n = 4 animals). The gene expression analyses from the collected EL fractions 
(E1-E4), along with the corresponding remaining lung homogenates (L1-L4) and the 
cellular debris from the BAL samples (BAL) were assessed by semi-quantitative RT-
PCR.  
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As shown in Figure 4.10.A, high expression of the epithelial markers was 
observed in the EL fractions (E1-E4). Especially the scgb1a1 (CC-10), sftpc (SP-C), 
and sftpb (SP-B) genes were highly expressed. In the epithelial samples the pump 
markers present in the AEC, Atp1α1 and Atp1β1, were also expressed. Moreover, the 
binding protein E-cadherin, encoded by the cdh1 gene, responsible for the maintenance 
of the epithelial cell polarity, was also amplified in the EL samples. On the contrary, the 
water channel aquaporin (AQP) 5, used as a marker for ATI cells, was not detectable. It 
was then suspected that the EL procedure might not be suitable for isolating RNA from 
type I pneumocytes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: Reproducibility of the EL technique. Cell type-specific marker expression analysis  from 
four EL fractions (E1-E4) and their corresponding lung homogenates (L1-L4) were analysed by semi-
quantitative RT-PCR. Cell debris from a bronchoalveolar lavage (BAL) sample was also included. A) 
Epithelial cell type-specific marker amplification. B) Amplification of fibroblast, smooth muscle and 
endothelial cell type-specific markers. GAPDH served as internal loading control. -RT: negative control 
for the RT step lacking RNA template. +RT: positive control for the RT step containing murine total 
RNA. -PCR: negative control for the PCR step with H2O as template +PCR: positive control for the PCR 
step containing mouse genomic DNA (n = 4). 
 
As depicted in Figure 4.10.B, many non-epithelial markers were analysed, such 
as the fibroblast marker collagen Iα1 (col1a1) and the SMC markers: calponin (cnn1), 
α-SMA and myosin (myh1l). None of the previously mentioned markers were amplified 
in the EL samples, indicating a reproducible pure RNA epithelial isolation by this 
sftpb 
sftpc 
aqp5 
cdh1 
atp1a1 
atp1b1 
scgb1a1 
gapdh 
-RT +RT -PCR +PCR E1 E2 E3 E4 L1 L2 L3 L4 BAL 
 
A 
E3 +RT 
col1a1 
cnn1 
acta2 
myh11 
pecam1 
gapdh 
-PCR +PCR E1 E2 E4 L1 L2 L3 L4 BAL -RT 
B 
RESULTS 
 
66 
 
method. Expression of the pecam1 gene was observed in the sample E3. As this 
contamination was only elevated in one sample, it was not considered a major drawback 
of the method. The cellular debris, contained in BAL fluid, exhibited almost the same 
gene expression pattern as the EL fractions. This could be explained by the fact that the 
majority of the cells present at the respiratory acini are macrophages, whose main 
function, at basal state, is to clear the alveolar ducts and alveoli of inhaled antigens and 
dead cells. These macrophages possibly express epithelial markers as they also 
phagocytace dead epithelial cells. Possible could be also that the BAL procedure itself 
disrupted partially the epithelium, dragging along some epithelial cells. 
Taken together, a constant reproducibility of the method was demonstrated by 
the similar gene expression profiles from the four different EL. Both RNA from 
proximal and distal situated cells was collected. This RNA highly expressed epithelial 
markers and non-epithelial marker expression was absent. In addition, the use of 
intron-spanning primers could ensure genomic DNA free samples. 
 
4.3.4 Epithelial lavage effect on the lung morphology  
Lung slices from both saline-lavaged and GI-lavaged organs, were probed by 
immunohistochemistry so to evaluate the effect of the EL technique on the lung 
architecture. For this reason, antibodies against two different layers of the lung were 
used: the epithelial sealing junction zonula occludens (ZO-1, or also called tight 
junction protein 1 -TJP1-), responsible for maintenance of the epithelial cell polarity 
(Abraham et al., 1999; Stevenson et al., 1986) and the α-SMA antibody, which was 
chosen to stain the smooth muscle layer of the lung.  
As depicted in Figure 4.11.A, the pronounced ZO-1 staining on saline-treated 
lungs (control) was localised along with the intact epithelium. Furthermore, ZO-1 was 
localised on the GI-lavaged lung slices on the disrupted epithelial cells at the airways 
and in the remaining, non-disrupted epithelial layer. On the contrary, as illustrated in 
Figure 4.11.B, the staining for α-SMA was comparable after both saline and GI 
treatments.  
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Figure 4.11: Epithelial cell disruption by GI. Immunohistochemistry of A) ZO-1 and B) α-SMA was 
performed on control lungs (saline-treated) and lungs treated with 1:20 GI for 30 seconds. Lower (10x, 
upper row) and higher magnification (20x, lower row) are depicted. Scale bar = 20 µm (n = 3). 
 
The fainter staining of ZO-1 on the right columns indicated that the epithelial 
cells were disrupted by the GI solution. The same staining levels of α-SMA on the 
vasculature led to the conclusion that the EL technique only disrupted the epithelial 
cells and not deeper tissue layers of the lung. It could be then morphologically assured 
that within a period of 30 seconds, using a 1:20 dilution of GI solution, a sample, free of 
RNA from adjacent, non-epithelial cells, could be collected. 
4.3.5 Steps to perform the epithelial lavage technique 
After establishing the optimal dilution, retention time of GI inside the lung, 
ensuring the reproducibility of the experimental approach, and the disruption of solely 
epithelial cells, the steps of the EL technique can be summarised as follows: 
 
1) Mice are sacrificed and placed in suprine position. The trachea is exposed via 
surgical dissection of the ventral neck and tracheostomised. A canula is 
inserted through and fixed.  
2) The lungs are carefully lavaged twice with saline (~500 µl each time) through 
the canula with the help of a 1 ml syringe. Both samples are collected together 
and snap frozen. 
3) Immediately after, 600 µl of 1:20 dilution of GI is carefully instilled and 
retained inside the lung for 30 s. 
4) The GI solution is then extracted from the lung and maintained in an 
Eppendorf tube, which contains 200 µl of undiluted GI.  
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5) An extra saline solution is instilled into the lung in order to extract the 
maximum amount of epithelial cells, which are disrupted and still laying in the 
alveolar spaces. This sample is carefully, repeatedly introduced and withdrawn 
(maximum three times).   
6) This fraction is subtracted and added on the sample obtained previously. 
Sample is either snap frozen or maintained in ice, if RNA is isolated 
immediately. 
7) Finally, RNA is isolated using the phenol/chloroform precipitation method. 
Briefly, the guanidinium isothiocyanate fraction (Roti-Quick1) is combined 
with phenol/chloroform (Roti-Quick2) to separate the RNA from the sheared 
DNA and proteins. RNA is then precipitated overnight by isopropanol 
(Roti-Quick3). An overnight precipitation is highly recommended, as well as 
the addition of glycogen (1 µl per extraction). Afterwards, disrupting salts are 
washed with 70% (v/v) ethanol and final RNA concentration is measured.  
4.3.6 Enrichment of the epithelial lavage fractions  
To accurately quantify the expression of epithelial cell type-specific markers in 
the EL samples, real-time RT-PCR was performed. The specificity of the PCR product 
was confirmed by melting curve analysis and additionally, Ct values were also 
calculated and graphically represented as Box and Whisker plots, which indicate the 
median values ± 25% and 75% confidence intervals and possible “outliers”. 
 The following genes were investigated by real-time RT-PCR: aytl2 (LPCAT), 
sftpc (SP-C), gabrp, titf1 (TTF-1), foxp2, pdpn (T1α), tjp1 (ZO-1), scgb1a1 (CC-10), 
acta2 (α-SMA) and pecam1, with n = 4-7 EL extractions. The analysis demonstrated 
that the markers, which identify ATII cells, were highly expressed in the EL samples 
(sftpc, titf1, and gabrp) (Figure 4.12). Furthermore, the CC-10 marker exhibited the 
highest expression ( Ct median = 7.25), indicating that the bronchial epithelium was 
effectively disrupted along with the alveolar epithelium during the EL approach. The 
pdpn, an ATI cell marker was also amplified ( Ct median = 2.00), thus the novel 
technique was also able to disrupt type I pneumocytes. However, an amplification of 
aqp5 (an ATI cell marker) by semi-quantitative RT-PCR was not observed (Figure 
4.10). On the contrary, the control markers for contaminating cells like endothelial and 
RESULTS 
 
69 
 
SMC were only present at very low levels (pecam1, Ct  median = -3.56; acta2, Ct  
median = -1.9). 
In summary, the quantification of marker expression by real-time RT-PCR 
demonstrated that the EL samples were enriched in epithelial markers and contained 
only RNA from cells present in both the bronchial and alveolar epithelium. These 
fractions expressed primarily Clara cell and ATII cell markers. 
 
  
 
 
 
 
 
 
 
 
Figure 4.12: EL gene expression pattern at basal state. Quantification of the EL gene expression 
profile (∆Ct) was assessed by real-time RT-PCR and represented in a Box and Whiskers plot. Median 
values are indicated with the bold, horizontal line. Epithelial and non-epithelial cell type-specific markers 
were analysed (n = 3). HPRT was used as reference gene. 
 
 
4.4 EPITHELIAL LAVAGE VERSUS PRIMARY ALVEOLVAR 
EPITHELIAL TYPE II (ATII) CELLS  
It has been repeatedly demonstrated that isolated primary ATII cells change 
their phenotype upon culture. The ATII cells gradually trans-differentiate into AEC type 
I-like cells between days 3 and 5 after isolation (Chen et al., 2004; Paine and Simon, 
1996). Moreover, the trans-differentiation degree depends on the matrix onto which 
these cells are plated (Gonzales et al., 2002) and on the presence of various stimuli 
(Thiery, 2002). Therefore, a comparison of gene expression levels between in vivo EL 
fractions and the type II pneumocytes plated for 1.5 days on uncoated dishes was 
performed. Moreover, the comparison included RNA of other samples obtained from 
the bronchoalveolar lavage cellular fraction (BAL), the corresponding remaining lung 
homogenates, and the mouse lung epithelial 12 (MLE 12) cell-line, and thus estimate 
how reliable, pure and enriched the EL fractions are. RNA was then isolated, and 
reverse transcribed. Large sample sizes (n = 4-7) from isolated primary ATII cells, lung 
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homogenates, BAL, and EL samples and a quantitative technique like real-time RT-
PCR were utilised to analyse their correspondent gene expression profiles. The Ct 
values obtained were calculated and plotted in a Box and Whisker graph. Statistical 
analyses were evaluated between the epithelial lavage and the ATII cells fractions.  
As depicted in Figure 4.13.A, the gabrp and aytl2 markers were significantly 
higher expressed in the EL fractions than in the isolated ATII cells (p ≤ 0.01). The 
higher expression of gabrp could be due to the fact that gabrp is also synthesised by 
BEC (Chen et al., 2004), cells that are also disrupted during the EL extraction. As 
expected, the relative expressions of scgb1a1 and pdpn were also significantly higher in 
the EL fractions, although not absent in the ATII samples (p = 0.02 and p = 0.04, 
respectively) (Figure 4.13.B). The expression of scgb1a1, a cell type-specific marker for 
Clara cells positioned at the proximal area of the lung, in the isolated ATII cell fractions 
could mainly be due to bronchial cell contamination during cell extraction.  
Interestingly, the analysed SMC marker (acta2) was not detected in the EL 
samples, in contrast to the high expression levels exhibited by the isolated primary ATII 
cells (p = 0.09), either due to a contamination of SMC during the extraction or it may be 
derived from a rapid trans-differentiation of ATII cells into mesenchymal-like cells 
(Figure 4.13.C). Moreover, the most abundantly expressed marker in the plated ATII 
cells was the sftpc. The titf1 and foxp2 markers were expressed at comparable levels in 
both the EL and isolated primary ATII cell samples, with pecam1 expression 
completely absent in both fractions (Figure 4.13.A and 4.13.C). Thus, the EL samples 
represent a more pure fraction than do the isolated primary ATII cells, in that the cell 
type-specific markers for smooth muscle and endothelial cells were not amplified. 
Furthermore, cell-specific markers for BEC and type I pneumocytes were present in the 
ATII cell samples, as well as in the epithelial lavage fractions.  
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Figure 4.13: Comparison between the EL fractions with other RNA isolations by real-time 
RT-PCR. EL fractions (E) were compared to the bronchoalveolar lavage cells (B), isolated primary ATII 
cells plated for 1.5 days (A), lung homogenates (L) and the MLE 12 cell-line (M) by real-time RT-PCR. 
Box and Whisker plots represent median values (bold horizontal lane) ± 25% and 75% confidence 
intervals and possible “outliers” of ∆Ct values. HPRT was used as reference gene. *: p<0.05 for the 
comparison between the EL and ATII cells fractions (n =2). 
 
Previously it was shown by semi-quantitative RT-PCR that the EL gene 
expression pattern was similar to the BAL fraction (Figure 4.10). Therefore, the 
quantification by real-time RT-PCR was strictly required to analyse, if the EL contained 
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solely epithelial cells or also a proportion of immune cells. Once performed, it could be 
concluded that the EL samples were not contaminated with macrophages, as the 
expression pattern did not exhibit any similarities. It was then demonstrated that the EL 
samples only contained RNA from disrupted epithelial cells. Therefore, the two BAL 
performed prior to the EL extraction were efficient enough to clear the pulmonary 
airways of dead and immune cells. Additionally, lung homogenate samples highly 
expressed all of the studied markers, while the MLE 12 cell-line did not express any of 
the markers analysed. 
In summary, the mRNA expression profiles proved that macrophages or dead 
cells did not contaminate the epithelial lavage samples, as the BAL expression profile 
did not compare with the epithelial lavage fractions. Surprising was the observation that 
the gene expression profile from MLE 12 did not demonstrate any expression of the 
markers analysed, although sftpc has been reported to be detectable on this 
immortalized cell-line (www.atcc.org). The comparison between the murine epithelial 
cell-line, freshly isolated ATII cells, lung homogenates and epithelial lavage 
extractions, led to the confirmation that the EL method is highly enriched in epithelial 
markers and it is not contaminated by mRNA from immune, smooth muscle or 
endothelial cells. Furthermore, as the gene and protein expression profile of the type II 
pneumocytes change upon culture (Chen et al., 2004; Paine and Simon, 1996), the 
physiological transcriptional and translational profiles reported thus far have not 
represented the real gene expression pattern of the ATII cells in vivo. The EL method 
would then be useful for exploring epithelial in vivo gene expression profile, technique 
by which cell isolation or tissue section preparation are avoided and thus modifications 
to the gene expression pattern are prevented. 
 
4.5 MARKER GENE EXPRESSION IN EPITHELIAL LAVAGE 
SAMPLES AFTER TGF-β1-INSTILLATION 
The efficient administration of the TGF-β1 ligand into the murine lung by the 
OT instillation and the isolation of pure RNA from the respiratory epithelial layer in 
vivo have been previously demonstrated (Figure 4.3 and 4.10, respectively). The 
combination of both techniques would represent a powerful tool to study marker gene 
expression in response to TGF-β1 in the epithelium in vivo. Thus far, it has been 
described that TGF-β1 can regulate gene expression in the respiratory epithelium, 
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playing an important role in the regulation of  the epithelial pumps and channels (Frank 
et al., 2003) and in the induction of EMT on the ATII cells (Kim et al., 2006; Willis et 
al., 2005). This study was focused in the latter effect, the TGF-β1-induced EMT on the 
epithelium. For this reason, markers that determine the EMT process in the lung, 
previously demonstrated to be regulated by TGF-β1, were analysed. To do so 2.5 ng/µl 
of TGF-β1 ligand (80 µl total volume) were OT instilled to the mice and after 8 h, the 
EL technique was performed. Once the RNA was isolated and reverse-transcribed, the 
cDNA was subjected to real-time RT-PCR. The genes analysed included EMT markers, 
both epithelial (E-cadherin -cdh1-, and occluding -ocln-) and mesenchymal markers 
(fibroblast specific protein 1 -s100a4-, α-SMA -acta2-, and vimentin -vim-). The β-
catenin1 -ctnnb1- marker can be considered both an epithelial and/or a mesenchymal 
marker, as it can drive or repress the EMT process, depending on the cell context. The 
transcriptional expression of TGF-β1 early target genes, serpine1 and ctgf was also 
included, in order to control ligand activity inside the lung.  
The gene expression patterns of both the untreated mice (naïve) and the 
saline-treated mice (NaCl, 80 µl total volume, sacrificed after 8 h) were also examined 
(n = 5 per condition). The different treatments were statistically compared by the 
Student’s t-test, as follows: naïve vs. saline-treated group and saline- vs. TGF-β1-treated 
mice. The first comparison served as control for the unspecific gene regulation due to 
the stress induced to the animals during the instillation. The latter comparison served to 
analyse the specific TGF-β1-induced gene regulation. 
As is evident in Figure 4.14, the serpine1 and ctgf gene expression was 
upregulated when TGF-β1 was administered, indicating that the recombinant ligand 
reached the lung and was active in situ. However, an upregulation on both genes was 
also observed in the saline-treated mice. The comparison between the saline- and TGF-
β1-treated animals led to the conclusion that only the serpine1 gene expression was 
significant (p<0.05) and that the TGF-β1 itself could specifically induce serpine1 
upregulation.  
Additionally, the epithelial markers cdh1 and ocln were less expressed in the 
TGF-β1-treated mice, when compared to the saline-treated mice, being the 
downregulation significant. However, the cdh1gene expression remained at the same 
levels as the naïve expression. The dual functional molecule, ctnnb1, exhibited a 
significant upregulation in the TGF-β1-treated compared to the saline-treated mice 
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(p<0.01). This leads to the conclusion that the ctnnb1 gene was higher express, 
promoting the transcriptional activation of mesenchymal markers.  
Furthermore, the mesenchymal markers included in the analysis, FSP1, α-SMA, 
and vimentin, did not demonstrate any significant specific regulation due to the TGF-β1 
instillation, although a tendency to higher expression compared to untreated animals 
could be observed after 8 h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14: Marker gene expression in EL upon TGF-β1 stimulation. EL samples from mice 
orotracheally instilled with TGF-β1 or saline and control mice (n = 5 per condition) were subjected to 
real-time RT-PCR. Animals were sacrificed after 8 h and EL extractions were performed. Markers for 
controlling TGF-β1 stimulation (PAI-1 and CTGF) and the EMT process: epithelial markers (E-cadherin 
and occludin), mesenchymal markers (α-SMA, FSP-1, and vimentin), and epithelial-mesenchymal 
marker (β-catenin) were analysed. Data represent the mean ± SD. HPRT was used as reference gene. *: 
p<0.05 for comparison between naïve vs. saline-treated and saline- vs.TGF-β1-treated samples (n=3). 
 
In summary, the expected upregulation of the mesenchymal markers after 
TGF-β1 instillation was not observed, when a single application of the recombinant 
ligand at a concentration of 2.5 ng/ml was utilised. However, a downregulation of the 
epithelial markers, cdh1 and ocln, was evident. Furthermore, an upregulation of the 
β-catenin molecule, responsible for the maintenance of adherens junctions and 
co-activator of mesenchymal markers on liberated, non-attached, cells was significant. 
Therefore, this indicates that TGF-β1 can induce changes on the gene expression of 
epithelial cells, but 8 h of retention time within the lung may not be sufficient to study 
the EMT process by this method; or alternatively, the amount of epithelial cells 
undergoing EMT may be below the detection level of this thechnique. 
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5 DISCUSSION 
 
5.1 OROTRACHEAL INSTILLATION 
Direct drug delivery into the lung provides novel pathways, not only to treat the 
respiratory organ, but also to cure systemic diseases (Sakagami, 2006). The advantages 
of this therapeutic approach are the high rate of drug absorption that the lung exhibits, 
due to its highly vascularized respiratory mucosa, large absorptive surface area, and its 
relative low enzymatic activity (Gonda, 2006; Patton et al., 2004). Therefore, the above-
mentioned properties facilitate the absorption of substances into the lung and further 
into the systemic vasculature.  
The lung is an organ constantly exposed to airborne particles, potential 
pathogens, and toxic gases contained in the inspired air, what naturally leads to the 
development of efficient control barriers i.e. chemical (surfactant lipids), mechanical 
(sneezing), and immune defense mechanisms (Nicod, 1999; Twigg, 1998). These well-
regulated, coordinated components need to be bypassed in order to ensure an efficient 
drug deposition and absorption. These pitfalls have challenged the efforts to deliver 
drugs into the lung, either for systemic or local healing.  
In the murine model utilised in this study, the epithelial lining fluid, alveolar 
macrophages absorption, and the epithelium itself were the defense barriers needed to 
be overcome in order to facilitate an efficient drug delivery. Among them, it is believed 
that the epithelial layer is the main barrier restricting the movement of drugs, water, and 
solutes from the airway lumen into the blood circulation (DeFouw, 1983; Schneeberger, 
1978).  
Different methods were analysed in order to characterise the instillation 
approach that could yield the best deposition rates. A preliminary experiment was 
performed in which five different instillation techniques, using the 1% Toluidine Blue O 
solution, were compared. The technique that would result in a good peripheral 
distribution into all the five lobes of the lung, using a minimal volume, would be the 
approach to use in future experiments. Among them, the orotracheal aspiration (OT) of 
80 µl of 1% Toluidine Blue O solution demonstrated a broad and homogenic 
distribution of ink throughout the lung, including the distal parenchyma, adjacent to the 
pleural surface, confirming previous observations, which utilised the Evans Blue dye 
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(Lakatos et al., 2006) (Figure 4.1). Moreover, it has been previously shown that this 
nonsurgical procedure results in a good bilateral and uniform distribution of suspended 
particles (Lakatos et al., 2006; Rao et al., 2003). Interestingly, the survival rate after the 
OT administration was almost 100% and multiple applications (reaching six within 28 
days, data from a non-related project) were possible. Furthermore, the duration of the 
whole procedure was very fast (around two minutes), required minimal training, no 
sophisticated laboratory equipment, and the mice recovered within seconds without any 
sequelae. 
Among the methods evaluated, the intratracheal (IT) delivery also yielded a 
good deposition rate; however, a larger volume (200 µl) was required to cover the same 
proportion of lung areas as in the OT approach. The IT method also resulted in a non-
uniform distribution within the lung (the instilled particles were predominantly retained 
in the large conducting airways near the hilum) (Lakatos et al., 2006; Pritchard et al., 
1985). Nevertheless, this method has been frequently utilised for the mouse model of 
bleomycin-induced PF (Lindenschmidt et al., 1986; Shahzeidi et al., 1993). 
Furthermore, direct intubation of the trachea, performed during the IT and microspray 
methods, is extremely challenging in mice and the mean survival rate is low (Guilbault 
et al., 2005). Intranasal aspiration has been reported to be adequate for inducing viral or 
bacterial invasion, but unsuitable for leading substances directly to the lung, as 50% of 
the administered material is trapped in the nasal passages (Eyles et al., 2001), a feature 
that was also recognised in the present study. The nebulisation approach exhibited some 
drawbacks, in that, only 5% of the lung was covered by the ink, specialised equipment 
was needed, and large amounts of the particulate insult were consumed, with the exact 
inhaled dose being impossible to estimate (Hanson et al., 1985).  
In conclusion, the method chose to instill TGF-β1 into the lung was the OT 
approach, as it generated the best results when compared to other drug delivery 
methods, like the intratracheal, intranasal, nebulisation, and microspray techniques. 
 
5.2 TGF-β1-INDUCED SIGNAL TRANSDUCTION AND GENE 
TRANSCRIPTION  
The development of TGF-β1 transgenic animal models has overcome the 
necessity of multiple administrations of ligand and has provided useful insights about its 
role in the lung. However, some drawbacks are encountered along with these models. 
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For instance, the TGF-β1 transgene is expressed throughout the lifetime of the animal, 
resulting in abnormal lung development (Zhou et al., 1996). Furthermore, a transient 
transgene approach was also achieved. In this case, a recombinant, replication-deficient, 
and mutant adenovirus (AdTGF-β1223/225), which renders the biological active form of 
TGF-β1, was intratracheally instilled into rats (Sime et al., 1997) or mice (Kolb et al., 
2001). The animals showed mononuclear cell accumulation between day 3 and day 14 
and a progressive fibroblast accumulation after day 14. This overexpression resulted in 
an extensive and persistent fibrosis, demonstrating the crucial role of TGF-β1 in the 
pathogenesis of PF. Moreover, the conditional overexpression of TGF-β1 has also been 
achieved using a triple-transgenic construct under a tetracycline operator coupled to the 
CC-10 promoter, as a model of BPD (Vicencio et al., 2004). However, through these 
methods, the induction or repression of the early-responsive gene transcription upon 
TGF-β1 in vivo could not be studied, as the exact initiation time of TGF-β1 signalling 
inside the cells cannot be determined.  
The delivery of recombinant cytokines is limited by their short half-life, cost, 
and the difficulties encountered by a repeated ligand administration (lower survival 
rate). However, in this report the ligand was administered, not to initiate a fibrotic 
response, but to examine the epithelial cell response upon TGF-β1 in the early time 
points. A single instillation of ligand was sufficient to promote signal transduction and 
gene transcription in these cells.  
The response to TGF-β1 was analysed in this report by using the Western blot, 
semi- and quantitative RT-PCR, specific TGF-β/BMP microarrays, and 
immunohistochemical approaches. It was demonstrated that the TGF-β1 reached the 
lung, was still active, and that the lung epithelium responded intracellularly to the ligand 
(Figure 4.7). It was also proved that the TGF-β1 promoted a Smad-dependent signal 
transduction inside the cells (Figure 4.3) and the repression and activation of early-
induced gene transcription (Figure 4.4, 4.5, and 4.6).   
During the analysis of downstream signalling in lung homogenates, only the 
R-Smads, Smad2 and Smad3, were studied, as these two molecules are specifically 
phosphorylated in response to TGF-β1. Additionally, it has been reported a 
TGF-β1-induced activation of the BMP Smads, Smad1 and Smad5. This signalling 
pathway requires the presence of the ALK-1 receptor on the cell membrane, 
accompanied by the endoglin accessory receptor. However, these receptors have only 
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been found to be expressed in endothelial cells (Goumans et al., 2002; Miyazawa et al., 
2002), and not on epithelial cells, which are the target cells in the TGF-β1-instilled 
model used in this assay.  
It has been well established that the TGF-β1 ligand may stimulate various 
intracellular signalling pathways. Therefore, the study of the TGF-β signalling pathways 
has become more complex, as not only the Smad-dependent pathway may be active, but 
also, among others, the MAPK, PI3K, and JNK pathways can be activated, either 
dependently or independently of the Smad pathway (Derynck and Zhang, 2003; 
Roberts, 2002). In the current model, the Smad pathway was activated 30 min after 
TGF-β1 stimulation. Phosphorylation of both Smad2 and Smad3 was specific to the 
TGF-β1 instillation and was independent of the TGF-β1 concentration, as the 
phosphorylation signal was observed after low (0.25 ng/µl) and high (2.5 ng/µl) 
concentrations of ligand. Nevertheless, the activation pattern was different between both 
R-Smads, while phospho-Smad2 was constantly activated, the Smad3 phosphorylation 
kinetics demonstrated an early response after 30 min and a late response after 6 h. 
However, the phospho-Smad3 signal was also found in saline-treated and naïve murine 
lungs, indicating that the Smad3 activation occurred at basal state in the lung, with the 
phosphorylation signal being stronger when TGF-β1 was present (Figures 4.3.A and 
4.3.B). 
Additionally, AKT phosphorylation was observed on every mouse submitted to 
OT instillation, and thus not only on mice treated with the TGF-β1-diluted fractions, but 
also in those treated with the carrier. These saline-treated samples served as controls for 
an indirect, unspecific pathway activation. It could be then concluded that the AKT 
phosphorylation was not a TGF-β1-specific response, but due to the stress conditions 
produced during the treatment (Figures 4.3.A and 4.3.B). However, this activation may 
be key, together with the activation of the Smad-dependent pathway, for EMT induction 
in the lung (Bakin et al., 2000). The other Smad-independent pathways, the MAPK and 
JNK pathways were activated by neither the OT method, nor the TGF-β1 instillation.   
The TGF-β1-induced regulation of gene expression was studied at the RNA 
level by RT-PCR (Figure 4.4) and a TGF/BMP-specific microarrays (Figure 4.5). It was 
confirmed that the serpine1, ctgf, gadd45b, and junb were upregulated upon TGF-β1 
application. However, the observed smad7 and junb upregulation in the 
semi-quantitative studies could not be confirmed by microarray, but the serpine1 
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upregulation (ctgf and gadd45b genes were not present on the utilised membrane). The 
gadd45b upregulation was reported to be very fast upon TGF-β1 administration, 
mediating TGF-β-induced p38 activation (Takekawa et al., 2002). The importance of 
the ctgf overexpression was studied by adenoviral gene transfer in the rat lung; in which 
severe fibrosis was developed although only transiently in rat lungs (Bonniaud et al., 
2003). 
The specific TGF/BMP superfamily microarrays, spotted with genes known to 
be regulated by either the TGF-β and/or BMP family ligands, showed the 
downregulation of a high number of genes upon TGF-β1 administration (Figure 4.5). 
Having in mind that the BMP and TGF-β signalling pathways have opposing effects; it 
follows that TGF-β1 may downregulate many BMP-induced genes in the pulmonary 
organ. For instance, the gene transcription of the BMP-4 ligand was strongly repressed 
and simultaneously, its direct inhibitor, Noggin, was upregulated upon TGF-β1 
stimulation. The inhibitor Noggin prevents BMP-4 interaction with the corresponding 
cell surface receptors (Zimmerman et al., 1996). The downregulation of the distal-less 
homeobox 2 (dlx2) by TGF-β1 stimulation in the lung has not been previously reported; 
however, BMP-2 ligand stimulates the expression of this gene in chondrocytes (Harris 
et al., 2003). Moreover, the RNA expression of the inhibitor of differentiation 2 (idb2) 
was also downregulated upon TGF-β1 stimulation, consistent with other studies 
(Kowanetz et al., 2004). It has also been previously demonstrated that the BMP-7 
antagonises the TGF-β1-mediated collagen induction through the Id2 molecule (Izumi 
et al., 2006). The accessory TGF-β receptor type III betaglycan, was found to be 
downregulated in the murine lungs treated with TGF-β1 for 6 hours. Betaglycan may 
act as a TGF-β antagonist, as it does not have an intrinsic signalling function and thus 
impairs binding of the TGF-β ligand isoforms to their corresponding signalling 
receptors (Eickelberg et al., 2002; Lopez-Casillas et al., 1994). Thus, TGF-β1 may 
repress this antagonistic receptor to longer potentiate its effects on the target cells. 
Furthermore, the Smad6 downregulation observed upon TGF-β1 stimulation inhibits the 
negative-feedback regulation of the TGF-β pathway (Imamura et al., 1997). 
On the contrary, various genes were upregulated upon TGF-β1 stimulation. The 
TGF-β1 induction has been previously demonstrated in other models for serpine1 
(Dennler et al., 1998; Jakowlew et al., 1997). Moreover, the role of serpine1 in PF has 
already been reported by using PAI-1-deficient mice, which were protected from 
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bleomycin-induced PF, and by using PAI-1-overexpressing mice that showed higher 
hydroxyproline content (collagen accumulation) leading to impairment of the gas 
exchange (Eitzman et al., 1996). Furthermore, the tgfbi was also upregulated upon 
cytokine application, following previously published data (Skonier et al., 1992). The 
tgfbi gene is principally expressed in the bronchial smooth muscle cells (SMC) (Billings 
et al., 2000). Members of the GDF family were also upregulated upon TGF-β1 
stimulation, more specifically the GDF1, GDF11, GDF2, and GDF8 members; 
however, the role of the GDF family in the lung under TGF-β1 influence has not been 
studied thus far. The BMP and activin membrane-bound inhibitor (BAMBI) was also 
upregulated by TGF-β1 stimulation. This transmembrane glycoprotein has been 
reported to be induced both in response to TGF-β and BMP signalling pathways, 
suggesting a probable negative feedback mechanism on the signalling of both 
subfamilies (Sekiya et al., 2004).  
An additional method, like the immunohistochemical analysis, demonstrated that 
the TGF-β1-responsive cells were situated in the epithelial layer: the bronchial epithelial 
(BEC) and the alveolar epithelial cells (AEC), at the proximal and distal regions of the 
lung, respectively. Both the cell types localised for phospho-Smad2 and PAI-1, well 
characterised downstream molecules of the TGF-β pathway (Figure 4.7).  
In Figures 4.3 and 4.4, it is evident that an activation of the downstream 
molecules (at the protein and RNA levels) does not always occur, but this was 
dependant on the samples utilised. This could be due to several reasons. Some silent 
pathological conditions affecting the murine lung (pulmonary edema, repeated mucosal 
injury, and inflammatory conditions), may lead to changes in the tissue composition and 
therefore, affect the permeability properties of the epithelium (Audi et al., 1999). In 
order to avoid these different responses, every treatment was performed on littermates 
and mice were always hosted under same conditions; however, it is sometimes not 
possible to distinguish if an animal is or was previously affected by any of these 
pathologies. Furthermore, the inter-animal variability found between individuals of the 
same species may play a crucial role in these variations. Another explanation is that the 
complete instilled dose of ligand may not reach the lungs, due to misdirected 
application of the liquid to the gut. 
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5.3 EPITHELIAL LAVAGE OPTIMISATION 
Following the necessity of finding novel pulmonary epithelial cell-specific 
markers expressed in vivo, the development of a novel method for RNA isolation was 
indispensable. An “epithelial lavage” (EL) extraction was then optimised in the 
laboratory permitting the study of the lung epithelium gene expression profile in vivo. 
The novel method avoids contamination by other cell layers of the lung and provides a 
highly enriched and pure epithelial mRNA fraction. 
Several optimisation steps were performed. The optimal dilution of guanidinium 
isothiocyanate (GI) (Figure 4.8) and the optimal retention time within the lung, 
conditions in which the maximum amount of epithelial cells could be disrupted, were 
assessed (Figure 4.9 and 4.11). Finally, the technique was demonstrated to be 
reproducible and the specificity and purity of the RNA epithelial samples were validated 
by quantitative RT-PCR (Figure 4.10 and 4.12).   
Pulmonary epithelial tissue consists of many cell types, including Goblet, Clara, 
type I and II alveolar epithelial cells (AEC), cuboidal and cylindrical ciliated cells. 
These cells have a different morphology, secrete diverse products, but as a whole, they 
form the first barrier between the inspired air and the host and regulate the response to 
external stimuli. During EL extraction, RNA from different cell types present at the 
epithelium was isolated (Figure 4.10). Therefore, the results obtained through the EL 
samples are a representation of the gene expression profile from different epithelial cell 
types in vivo. In order to certainly ascribe a newly discovered marker to a specific cell 
type, immunohistochemisty or in situ immunofluorescence could be employed.  
It is of importance to characterise the gene expression profile of the epithelial 
cells under normal conditions and compare this with the expression pattern of epithelial 
cells from injured lungs. The questions to be answered are, what is/are the trigger/s of 
these changes and which are the alterations that the cell suffers to become malignant, 
apoptotic, or hyperplastic. This knowledge will be essential for the development of new 
drugs, as the pulmonary epithelium plays a crucial role in various pulmonary diseases, 
for instance, in idiopathic pulmonary fibrosis (IPF) (Geiser, 2003a), or acute lung injury 
(ALI) (Geiser, 2003b).  
Use of the novel method described in this report would help explore AEC gene 
expression profiles in vivo. However, a drawback of this method is that only between 
400 and 1000 ng of total RNA can be collected, and thus a high efficiency reverse 
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transcriptase is required. With regard to the reverse transcribed cDNA from EL samples, 
it consistently and reproducibly amplified products up to 1000 base pairs, leading to the 
conclusion that the isolated RNA integrity was good. If a genomic microarray analysis 
was to be performed, larger quantities of RNA (micrograms) would be demanded 
(Jenson et al., 2003). To be able to achieve those quantities, a pool of samples or an 
additional pre-amplification step would be necessary. However, these solutions are sub-
optimal, as the sample pool may mask some crucial gene regulation (Peng et al., 2003) 
and complex pre-amplification reactions may alter the relative abundance of specific 
transcripts and thus yield erroneous results in the subsequent microarray analyses 
(Wilhelm et al., 2006). For instance, the T7 pre-amplification technique leads to the 
underrepresentation of 5´-terminal transcripts (Wilhelm et al., 2006).  
 
5.4 EPITHELIAL LAVAGE VERSUS ISOLATED PRIMARY 
ATII CELLS  
In order to validate the specificity and purity of EL extractions, their gene 
expression profiles were compared to primary ATII cells, the murine lung epithelial 12 
cell-line, the cellular fraction of the BAL fluid, or whole lung homogenates after EL by 
semi-quantitative and real-time RT-PCR. Using these techniques, it was demonstrated 
that not only the EL extraction, but also the primary isolated ATII cells, contained 
several types of epithelial cells like Clara and ATI cells. The isolated primary ATII cells 
were as well accompanied by non-epithelial cells (demonstrated by the amplification of 
the acta2 transcript, specific marker for SMC) (Figure 4.13). Therefore, the EL fractions 
were more pure than the primary ATII cells, in that they did not contain markers from 
non-epithelial cell types. The gene expression of non- and epithelial markers found in 
the isolated primary type II pneumocytes fractions can be due to the trans-differentiation 
that these cells suffer upon culture. These cells trans-differentiate into intermediate 
cells, which express ATI and mesenchymal markers, independently on the matrix onto 
which they were plated (Chen et al., 2004; Gonzalez et al., 2005). This transition of 
epithelial to mesenchymal cells was not induced in the current study by any additional 
external stimulus, than from the cocktail of GF present in the serum added to the 
DMEM medium, in where the cells were grown. The exact concentration of TGF-β1 
present in the commercial FCS is not clearly described, but some reports have estimated 
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the TGF-β1 secretion levels of ATII cells in culture to about 3.5 ± 0.5 ng/ml after 24 h 
(Kumar et al., 1996). 
The EL fractions were not only compared to the isolated primary type II 
pneumocytes, but also to the MLE 12 cell-line, which did not express any ATII cell 
marker, although they have been reported to synthesise the SP-C (Wikenheiser et al., 
1993). It was also ensured that the EL fractions did not contain immune cells, as the 
comparison between both fractions was completely different, as assessed by quantitative 
RT-PCR (Figure 4.13). The complete comparison at the mRNA level between epithelial 
and immune cells was not possible to pursue, as no markers at the transcriptional level 
are currently available to detect specifically the later cell-type. Immune cells are 
currently isolated and identified by protein markers at their cell surface, known as 
cluster of differentiation molecules (Woolfson et al., 2006; Zola, 2001). However, the 
unique possible comparison performed using epithelial, endothelial and SMC markers, 
between both fractions, was completely different and thus, it could be concluded that 
the two bronchoalveolar lavages, undertaken prior to the EL, were efficient enough to 
remove lining cells and fluid and so to avoid contamination of the EL samples by 
immune cells. 
The gene expression profile from the remaining lung homogenates represented 
the cells, which were still present in the lung, after the EL extraction was completed. 
Expression of epithelial, endothelial, and SMC markers was evident. Interestingly, the 
pdpn and gabrp markers had a higher expression in the EL fractions than in the 
homogenates, leading to the conclusion that the ATI and ATII cells were highly 
disrupted by the EL (Figure 4.13).   
Of note, many previously reported markers are not as specific as they were 
originally thought to be. For instance, the atp1a2 was recently reported to be also 
expressed by type I pneumocytes and not only by ATII cells (Johnson et al., 2002). 
Moreover, different research groups have contradicting results on which cell-type 
expresses a specific biomarker, for example, the receptor for advanced glycation end 
products (RAGE) has been localised to both the ATI (Demling et al., 2006) and ATII 
cells (Morbini et al., 2006). Therefore, the definition of some cell-specific markers may 
vary with acquired data in the future. 
 After ascertaining that the EL was neither contaminated by immune cells nor 
endothelial or SMC, and that the fraction was highly enriched in epithelial markers; it 
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could be concluded that the EL technique represents a novel method for isolating RNA 
from the murine lung epithelium. Therefore, the study of the gene expression in vivo 
(where cell plating could be avoided) by the EL technique may constitute nowadays the 
unique approach to characterise the epithelial gene expression patterns at basal level.  
 
5.5 TGF-β1 AND THE LUNG 
Basal activity of the TGF-β pathway is required to regulate lung branching, 
maintain alveolar integrity and extracellular matrix (ECM) homeostasis, but an 
excessive, upregulated signalling would result in lung fibrosis, characterised by 
inhibited ECM degradation and enhanced ECM deposition. The TGF-β pathway has 
been implicated since many years in the pathogenesis of fibrosis based on its induction 
of matrix production and deposition on stromal cells in vitro, and its increased 
expression in fibrotic tissues from a variety of organs (Branton and Kopp, 1999).  
Not only TGF-β1 overexpressing mouse models have been developed 
(Discussion 5.2), but also the TGF-β-related deficient mouse models. For instance, the 
Smad3 knock-out (KO) mouse model was developed as the most pro-fibrotic activities 
of TGF-β are mediated by the TF Smad3, and Smad3 deficient mice demonstrated no 
fibrotic responses after bleomycin instillation (Flanders, 2004; Roberts et al., 2001). 
Additionally, the TGF-β1 null mouse demonstrated fewer fibrotic lesions and decreased 
RNA and protein expression of collagen I and fibronectin than did the wild-type after 
bleomycin administration (Zhao et al., 2002). Furthermore, the Smad3 KO mouse has 
been subjected to high local concentrations of TGF-β1 using the AdTGF-β1223/225 
adenovirus. In this case, the loss of Smad3-dependent signalling prevented the 
TGF-β1-induced ECM gene expression and blocked fibrosis progression; however, an 
emphysema-like phenotype was observed (Bonniaud et al., 2004).  
Regarding human disease, clinicians have found high TGF-β1 levels inside the 
lung under pathological conditions (El-Gamel et al., 1999). For instance, lung 
transplantation in the advanced medical therapies can be complicated by chronic 
rejection of the lung, which is associated with increased expression of TGF-β (El-Gamel 
et al., 1998). High levels of TGF-β1, both the active and latent form, have been found 
augmented following radiation therapy (Herskind et al., 1998), in accordance with the 
radiation mouse model (Rube et al., 2000). 
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Highly expressed TGF-β1 levels have been also related to other diseases, such 
as, ALI and bronchiolitis obliterans (BO), in which this cytokine plays a critical role. In 
the ALI disease, it have been demonstrated that TGF-β1 levels are critical to the 
development of pulmonary edema by increasing alveolar epithelial cell permeability 
(Dhainaut et al., 2003), whereas in BO the TGF-β1 is thought to induce BEC 
proliferation and myoblast trans-differentiation, leading to fibrous scarring of the 
respiratory and terminal bronchioli (Frost, 2002).  
 
5.6 TGF-β1 AND THE LUNG EPITHELIUM 
TGF-β1 and the pulmonary epithelial layer are highly integrated, as TGF-β1 is 
synthesised by many different cell types in the lung, but principally by the bronchial 
epithelium at basal state (Magnan et al., 1994). The activity of this ligand on the 
airways is related to cell growth, migration, and cell differentiation, which are directly 
relevant to airway physiology and pathophysiology (Duvernelle et al., 2003). 
Furthermore, TGF-β1 plays a key role in regulating airway production of ECM, as it 
induces the synthesis of matrix molecules, including fibronectin and tenascin, and 
represses the expression of proteases involved in matrix regulation, such as cathepsins. 
This cytokine also induces the production of integrins and adhesion molecules by 
epithelial cells (Branton and Kopp, 1999; Duvernelle et al., 2003). Furthermore, it 
promotes bronchial epithelial cell differentiation (Masui et al., 1986) and inhibits 
epithelial cell proliferation (Kasper and Haroske, 1996).  
However, not only augmented ECM production but also ineffective epithelial 
layer repair has been related to high levels of TGF-β1. For instance, the cytokine has 
been reported to potentiate AEC apoptosis by activating the Fas-mediated apoptosis 
pathway in these cells (Wang et al., 1999) and thus augmenting the extrinsic oxidative 
stress (Arsalane et al., 1997; Thannickal and Fanburg, 1995).  
The influence of the TGF-β1 cytokine on the epithelium has been studied on 
cell-lines and isolated primary ATII cells. Although differentiated ATII cell-lines are 
not currently available; nevertheless, several cell-lines with an epithelial origin have 
been submitted to TGF-β1 stimulation, such as, the A549 and RLE-6TN, and found to 
undergo EMT (Kasai et al., 2005; Willis et al., 2005). However, the cell-lines are 
limited in that they are immortalized and in many cases transfected and transformed, 
processes that change completely the gene expression of those cells (Malkinson et al., 
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1997). Regarding the isolated primary cells, the reproducible isolation method of viable 
ATI cells for in vitro studies has been recently developed (Dobbs et al., 1998). On the 
other hand, the ATII cells have been extenually studied, as their isolation protocol was 
already optimised thirty years ago (Dobbs et al., 1986; Dobbs et al., 1997) and shown to 
undergo EMT under TGF-β1 stimulation (Willis et al., 2005). Moreover, not only the 
TGF-β1 effect has been studied on alveolar epithelial cells, but also on the airway 
epithelial cells, both the bronchial and the Clara cells, promoting their cell apoptosis and 
differentiation (Pelaia et al., 2003; Zeng et al., 2001).  
 
5.7 ROLE OF TGF-β1 ON THE EPITHELIUM IN VIVO 
Thus far, it has been described that TGF-β1 can regulate gene expression in 
the respiratory epithelium, playing an important role in the induction of EMT on the 
ATII cells (Kim et al., 2006; Willis et al., 2005) and in the regulation of  the epithelial 
pumps and channels (Frank et al., 2003). The current study was focused more on the 
first regulationTGF-β1-induced EMT. The process of EMT occurs in vivo, playing a 
pivotal role in the cellular trans-differentiation during development and tumor 
invasiveness (Zavadil and Bottinger, 2005). The process of EMT is an example of 
epithelial cell plasticity, as during this trans-differentiation, the epithelial cell exhibits a 
loss of cell polarity, disassembly of cell adhesion systems (cdh1 and ctnnal -α-catenin- 
gene expression is absent), and an increased synthesis of molecules responsible for 
cell-motility. These modifications lead to morphological changes and acquisition of 
fibroblast-specific markers like α-SMA, vimentin, or fibronectin, features that enable 
cell movement and morphogenesis (Thiery and Sleeman, 2006; Zavadil and Bottinger, 
2005). The EMT process may be activated by various extracellular stimuli. TGF-β1-
induced EMT was the first to be described in mammary epithelial cells (Miettinen et al., 
1994). However, many members of the TGF-β superfamily initiate and maintain the 
EMT programme, by regulation of the Smad-dependent and -independent pathways 
(Thiery and Sleeman, 2006). On the contrary, BMP-7  has an opposite response as it 
notably inhibits EMT and fibrotic responses in several animal models (Zeisberg et al., 
2003). Furthermore, other signalling pathways promote EMT, including the Wnt and 
ET-1 pathways, among others (Jain et al., 2007; Radisky, 2005). 
The limitations of in vitro cell culture experiments in reflecting in vivo 
biology led to the initiation of the current study, as it has already been proven that 
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different specific cell culture conditions can affect the EMT response. For instance, the 
ECM on which the cells are attached dictates the EMT response (Willis et al., 2005; 
Zeisberg et al., 2001), maybe due to a combination of multiple factors including integrin 
signalling, cytoskeletal signalling through small G proteins, and signalling through GF 
bound to the matrix (Werb, 1997). Furthermore, the mixture of GF present in the serum 
can also modify the EMT response of these cells. Therefore, the EMT induction by 
TGF-β1 instillation, followed by direct RNA isolation of the epithelial cells, would shed 
light on the EMT process in vivo. 
A single instillation of TGF-β1 (2.5 ng/µl, 8 h) was found to induce gene 
expression modifications in the epithelial cells (Figure 4.14). For instance, the cdh1 and 
ocln genes were specifically transcriptionally repressed by TGF-β1 stimulation. 
Previous publications reported the Snail and Slug family to be responsible for the 
E-cadherin and occludin downregulation, this family of TF being as well positively 
regulated by TGF-β1 (Ikenouchi et al., 2003). The E-cadherin and occludin expression 
levels were found to be essential for the maintenance of the epithelial cell polarity 
(Zavadil and Bottinger, 2005). Therefore, since these two molecules related to adherens 
and tight junctions, were less expressed, it can be proposed that epithelial cell polarity 
was partially lost in the TGF-β1-treated mice.   
The E-cadherin gene expression level, expressed by the epithelial lavage 
samples (Figure 4.10) was downregulated upon TGF-β1 application, as assessed by 
quantitative RT-PCR (Figure 4.14). It has been previously demonstrated that NMuMG 
cells (mouse mammary epithelial cells) overexpressing Id2, exhibited partial resistance 
to TGF-β1-induced EMT by inhibiting the helix-loop-helix factor E2A, which is 
responsible for the suppression of the E-cadherin promoter (Kondo et al., 2004). In the 
current model, the downregulation of the Id2 molecule was confirmed by microarray 
and quantitative RT-PCR, on mice treated with TGF-β1. The Id2 downregulation was 
observed after 6 h of stimulation, prior to the E-cadherin repression, which was 
observed after 8 h. Therefore, it can be hypothesised that the downregulation of E-
cadherin could be due to the absence of the Id2 molecule. 
Interestingly, no mesenchymal markers were significantly upregulated apart 
from the β-catenin gene. This molecule can be considered either an epithelial or a 
mesenchymal marker, as it can drive or repress the EMT process. β-catenin is both an 
intracellular binding partner of the E-cadherins, and thus responsible for the 
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maintenance of adherens junctions (Zavadil and Bottinger, 2005) and a transcriptional 
co-activator, when the cell is freed from cell contacts (Behrens et al., 1996). 
Functioning as a transcriptional co-activator can induce mesenchymal gene transcription 
like α-SMA expression (Masszi et al., 2004) and EMT progression of tumor cells 
(Gilles et al., 2003). Furthermore, it has been localised to the nuclei of the epithelial 
cells in patients suffering from IPF (Chilosi et al., 2003) and published that the TGF-β1 
could induce β-catenin expression (Masszi et al., 2004; Tian et al., 2003), which 
correlates with the results of TGF-β1 OT instillation. Thus, the significant upregulation 
of β-catenin after 8 h could further promote the activation of transcription of 
mesenchymal markers.  
Furthermore, the rest of the mesenchymal markers included in the analysis, 
FSP1, α-SMA, and vimentin, did not demonstrate any significant upregulation due to 
the TGF-β1 instillation, although a tendency to a higher expression compared to 
untreated animals could be observed after 8 h. 
To sum up, the expected significant upregulation of the mesenchymal markers 
after OT TGF-β1 instillation was not observed in the current model, when a single 
application of the recombinant ligand at a concentration of 2.5 ng/ml was utilised. 
However, a significant downregulation of the epithelial markers, cdh and ocln was 
evident. Furthermore, an upregulation of expression of the dual molecule β-catenin 
molecule was significant. Therefore, the experimental procedure may be useful in that 
TGF-β1 induced some changes on the gene expression of the epithelial cells. In order to 
improve assessment of changes, the retention time of TGF-β1 within the lung could be 
varied, as 8 h may not be sufficient to detect a complete initiation of the EMT process. 
Furthermore, the ligand concentration used could be augmented in order to induce a 
faster cell trans-differentiation. Additional OT instillations of the cytokine to the mice 
may also help in the induction of EMT.  
The EMT process has been defined by simultaneous expression of epithelial and 
mesenchymal markers. However, it has not been established if the downregulation on 
epithelial markers occurs first, and later the upregulation of the mesenchymal markers is 
induced or vice versa. The simultaneous expression due to de novo synthesis of 
mesenchymal markers colocalising with previously expressed epithelial markers may 
occur sometime after the analysed 8 h. 
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Finally, it is important to stress that the potential source of the myofibroblasts 
may not be unique, but a combination of local, infiltrated bone marrow-derived cells, 
and trans-differentiated epithelial cells could contribute to the increase number of these 
active cells in the lung, which will form the fibroblastic foci, the hallmark of IPF.  
 
5.8 CONCLUSIONS AND PERSPECTIVES 
From the presented data, the following can be concluded: 
1. The OT instillation yields the best deposition rate for local delivery to the lung, 
when compared with intratracheal, intranasal, microspray, or nebulisation 
methods (Figure 4.1-4.2). 
2. The OT instillation of the TGF-β1 cytokine is sufficient to promote intracellular 
changes, both at the protein and RNA levels, at relatively low amounts of 
ligands and at early time points (Figure 4.3-4.6). 
3. Cells activated by OT-instilled TGF-β1 include alveolar and bronchial epithelial 
cells (Figure 4.7).  
4. The EL technique represents a novel approach to obtain an enriched RNA 
fraction from murine epithelial cells in vivo, without contamination of adjacent 
cell types (Figure 4.8-4.12). 
5. Comparison of the gene expression pattern between the EL technique, primary 
ATII cells, cells from the bronchoalveolar lavage, and cell-lines, demonstrated 
that the EL fractions do not contain immune, smooth muscle, or endothelial cells 
and are enriched in ATI and ATII cell markers (Figure 4.13). 
6. The TGF-β1 instillation combined with the EL demonstrated a loss of epithelial 
cell markers in response to TGF-β1 in vivo (Figure 4.14).  
 
The EL technique, which makes use of a diluted GI solution administered 
intratracheally, represents a novel method to specifically isolate RNA from the 
pulmonary epithelial layer, comprising the distal and the proximal epithelium. The 
samples are free of genomic DNA and of endothelial and mesenchymal markers. The 
RNA obtained represents the gene expression pattern of the epithelial layer in vivo as it 
is extracted directly from the murine lung. In this way, cell isolation or tissue section 
preparations are avoided and thus modifications to the gene expression pattern are 
prevented. This represents a key milestone, as it has been published that the chosen 
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method for handling with the samples (Curran et al., 2000) or the high probability of 
RNA degradation by endogenous RNases can modify the in vivo gene expression 
profile (Gonzalez et al., 2005; Kohda et al., 2000).    
Furthermore, the EL can also be used to analyse the uptake of different 
substances from the alveolar space into the epithelial cells, and their effect inside the 
cell (for example, the instillation of cytokines combined with the EL technique) can 
serve to study different processes in the murine lung in vivo. 
The future perspectives would be to analyse the gene expression profile of many 
other markers in the EL fractions by semi-, quantitative RT-PCR, and microarray. The 
large number of thus far known cell-specific markers could not be covered by the 
current report. The microarray, using the SMART™ pre-amplification method 
(necessary due to the low RNA concentrations obtained), which avoids the 
underrepresentation of 5´-terminal transcripts (Wilhelm et al., 2006), would shed light 
on the knowledge from the murine epithelial gene expression in vivo. Additionally, 
using the microarray technique, different samples could be compared, for instance, the 
EL fractions versus the mouse isolated primary type II pneumocytes or versus lung 
homogenates, or other epithelial cell-lines. Moreover, the comparison between EL 
fractions obtained from saline- and bleomycin-instilled mice could reveal modifications 
to the gene expression patterns in the epithelial cells in this model of IPF.  
A chromatin immunoprecipitation (ChIP) analysis could also be performed on 
these fractions (using the antibody against Smad3 as a precipitant) (Yu et al., 2008), in 
order to investigate TGF-β1 responsive genes in vivo in the epithelial layer. 
The EL method could also be optimised in the rat, an animal that possesses a 
more similar lung morphology to the human organ than do the mice. 
Furthermore, a more detailed study on the TGF-β1-induced EMT in the lung 
would be useful, to understand when EMT is initiated and which are the main 
early-modified markers in vivo. For this, different concentrations of TGF-β1, several 
stimulations and different retention time points could be studied. 
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Table A.16 : Primer sequences 
 
Table 17: Primer sequences used for semi-quantitative and real-time RT-PCR: The short gene name, 
forward and reverse primer sequences in 5´to 3´ orientation, and GeneBank™ accession number are 
listed. The specific primers used for quantitative RT-PCR are indicated by the addition of RT after the 
name of the gene. *: These primers were derived from Jernigan NL and Drummond HA, 2005. 
 
 
Gene Forward primer sequence (5´-3´) 
Reverse primer sequence (5´-3´) GenBank
TM 
Accesion Nr. 
α-SMA AGACAGCTATGTGGGGGATG GAAGGAATAGCCACGCTCAG NM_007392 
α-SMA-RT CTGACAGAGGCACCACTGAA CATCTCCAGAGTCCAGCACA NM_007392 
β-catenin-RT ACGCACCATGCAGAATACAA GGTGACCCAAGCATTTTCAC NM_007614.2 
*β-EnaC AAAGGCCTGCGCAGGAGGCG 
GCCACAG 
GATGGCCTCCACCTCACTGTCCGACTC NM_011325.1 
Atp1α1 GGGAAGGGGGTTGGACGA GGTGTGAGGGCGTTGGGG NM_144900 
Atp1β1 GGAGAAGAAGGAGTTTTTGGGCAG CTTCCTCTCTCCCCGTTCGTG NM_009721 
AQP5-RT CCTTATCCATTGGCTTGTCG CTGAACCGATTCATGACCAC NM_009701.4 
Calponin GGCCAAGACAAAAGGAAACA GACCTGGCTCAAAGATCTGC NM_009922 
CC-10-RT TGGATACCCTCCCACAAGAG AGGGCAGTGACAAGGCTTTA NM_011681.1 
Col1agen1α1 ACGTCCTGGTGAAGTTGGTC TCCAGCAATACCCTGAGGTC NM_007742.3 
CTGF CCCGCCAACCGCAAGATT AGGCGGCTCTGCTTCTCCA NM_010217 
CTGF-RT GCAGACTGGAGAAGCAGAGC GACAGGCTTGGCGATTTTAG NM_010217 
E-cadherin AGTTTACCCAGCCGGTCTTT AGGGTTCCTCGTTCTCCACT NM_009864 
E-cadherin-RT CAAGGACAGCCTTCTTTTCG TGGACTTCAGCGTCACTTTG NM_009864 
Fibronectin-RT GAGTGGAAGTGTGAGCGACA GCATCGTAGTTCTGGGTGGT NM_010233 
Foxp2-RT CTTGGAAGAATGCAGTGCGTC TTTTGTGACCTTCGCTTCTGG NM_053242.3 
FSP1-RT TTGTGTCCACCTTCCACAAA GCTGTCCAAGTTGCTCATCA NM_011311.1 
GABRP GCGCCTTGCTCAGTACACAA ACGTTCCTCCGAAGCTCAAAT NM_146017.2 
GADD45 AGGCGGCCAAACTGATGAATGT AGGTCTCGGGCTTCGGTTGTG NM_008655 
GAPDH ACCCAGAAGACTGTGGATGG TGTGAGGGAGATGCTCAGTG NM_001001303 
HPRT-RT TGCTGACCTGCTGGATTACA TATGTCCCCCGTTGACTGAT NM_013556.2 
JunB GCAGCTACTTTTCGGGTCAG TTCATCTTGTGCAGGTCGTC NM_008416.1 
LPCAT GGCTCCACATTCCTCCTACTTTG ATCTCCTCCACTGTCTTCCTTCG NM_145376.3 
Myosin GACAACTCCTCTCGCTTTGG GCTCTCCAAAAGCAGGTCAC NM_013607.1 
Occludin-RT GCTCTCTCAGCCAGCGTACT ATAGCCTCTGTCCCAAGCAA NM_008756.2 
PAI-1 TCATCAATGACTGGGTGGAA GCCAGGGTTGCACTAAACAT NM_008871 
PAI-1-RT CTTTACCCCTCCGAGAATCC GACACGCCATAGGGAGAGAA NM_008871 
PECAM-1 CCTTCACCATCAACAGCATCCA ATGGGTTCTGACTCCTGCAATT NM_008816 
PECAM-1-RT CACCTGCAAAGTGGAATCAA AGCAGGACAGGTCCAACAAC NM_008816 
proSP-B CCAAGAGTGTGAGGATATTGTCCA AAGGGCAGGGGAATGGGG NM_147779 
proSP-C CCAGGAGCCAGTTCCGCATC AGTGGTAGCTCTCCACACAGG NM_011359 
proSP-C-RT GCAAAGAGGTCCTGATGGAG ATGAGAAGGCGTTTGAGGTG NM_011359 
Smad7 TCTCCCCCTCCTCCTTACTC CAGGCTCCAGAAGAAGTTGG NM_008543.1 
Slug-RT GAAGCCCAACTACAGCGAAC AGGAGAGTGGAGTGGAGCTG NM_011415.2 
T1α-RT ACAGGTGCTACTGGAGGGCTT TCCTCTAAGGGAGGCTTCGTC NM_010329.1 
TTF-1-RT AGCTTCCGAAGCCGAAGTATC AGAACGGAGTCGTGTGCTTTG NM_009442.1 
Vimentin TGAAGGAAGAGATGGCTCGT TCCAGCAGCTTCCTGTAGGT NM_011701.3 
Vimentin-RT TGAAGGAAGAGATGGCTCGT TCCAGCAGCTTCCTGTAGGT NM_011701.3 
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Figure A.1.: Overview of the GEArray Procedure: Amplification and labelling by biotin-UTP of 
antisense RNA is followed by hybriditation on the GEArray  
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 
 
114 
 
Table A.17: Oligo BMP/TGF-β superfamily microarray 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gapdh: Glyceraldehyde-3-phosphate dehydrogenase 
Acvr1 : Activin A receptor type 1 
Acvr1b : Activin A receptor type 1B 
Acvr2 : Activin A receptor type 2 
Acvr2b : Activin A receptor type 2B 
Acvrl1 : Activin A receptor type 2-like 1 
Amh: Anti-Mullerian hormone 
Bambi: BMP and activin membrane-bound inhibitor 
Bglap1: Bone γ-carboxyglutamate protein 2 
Bmp1: Bone morphogenetic protein 1 
Bmp10: Bone morphogenetic protein 10 
Bmp15: Bone morphogenetic protein 15 
Bmp2: Bone morphogenetic protein 2 
Bmp3: Bone morphogenetic protein 3 
Bmp4: Bone morphogenetic protein 4 
Bmp5: Bone morphogenetic protein 5 
Bmp6: Bone morphogenetic protein 6 
Cdkn2b: Cyclin-dependent kinase inhibitor 2B (p15)  
Cer1: Cerberus 1 homolog  
Chrd: Chordin 
Grem1: Gremlin 1  
Col1a1: Procollagen type Iα1  
Col1a2: Procollagen type Iα2 
Col3a1: Procollagen type IIIα1  
Dlx2: Distal-less homeobox 2  
Lefty1: Left right determination factor 1  
Eng: Endoglin  
Evi1: Ecotropic viral integration site 1  
Fkbp1b: FK506 binding protein 1b  
Fos: FBJ osteosarcoma oncogen  
Fst: Follistatin 
Gdf1: Growth differentiation factor 1  
Gdf11: Growth differentiation factor 11   
Acvr1 Acvr1b Acvr2 Acvr2b Acvrl1 Amh Bambi Bglap1 
Bmp1 Bmp10 Bmp15 Bmp2 Bmp3 Bmp4 Bmp5 Bmp6 
Bmp7 Bmp8a Bmp8b Bmpr1a Bmpr1b Bmpr2 Cdc25a Cdkn1a 
Cdkn2b Cer1 Chrd Grem1 Col1a1 Col1a2 Col3a1 Dlx2 
Lefty1 Eng Evi1 Fkbp1b Fos Fst Gdf1 Gdf11 
Gdf2 Gdf3 Gdf5 Gdf6 Gdf8 Gdf9 Idb1 Idb2 
Idb3 Idb4 Cd79a Igf1 Il6 Inha Inhba Inhbb 
Inhbc Inhbe Itgb5 Itgb7 Ivl Jun Junb Lap3 
Lefty2 Igfbp3 Smad1 Smad2 Smad3 Smad5 Smad6 Smad7 
Smad9 Nbl1 Nodal Nog Pdgfb Plat Plau Runx1 
Runx2 Serpine1 Sox4 Stat1 Tgfb1 Tgfb1i1 Tgfb1i4 Tgfb2 
Tgfb3 Tgfbi Tgfbr1 Tgfbr2 Tgfbr3 Tgif Timp1 Zfhx1a 
PUC18 PUC18 PUC18 Blank Blank Blank Gapd Gapd 
Ppia Ppia Ppia Ppia Rpl13a Rpl13a Actb Actb 
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Gdf2: Growth differentiation factor 2 
Gdf3: Growth differentiation factor 3 
Gdf5: Growth differentiation factor 5   
Gdf6: Growth differentiation factor 6   
Gdf8: Growth differentiation factor 8   
Gdf9: Growth differentiation factor 9   
Idb1-4: Inhibitor of DNA binding 1-4 
Cd79a: CD79 antigen (immunoglobulin-associated α) 
Igf1: insulin-like growth factor 1  
Il6: interleukin 6 
Inha: inhibin α  
Inhba: inhibin β-A  
Inhbb: inhibin β-B  
Inhbc: inhibin β-C  
Inhbe: inhibin β-E  
Itgb5: Integrin β 5  
Itgb7: Integrin β 7 
Ivl: Involucrin 
Jun: Jun oncogene  
Junb: Jun-B oncogene  
Lap3: Leucine aminopeptidase 3  
Lefty2: Left-right determination factor 2  
Igfbp3: Insulin-like growth factor binding protein 3  
Smad1: MAD homolog 1-7 
Smad9: MAD homolog 9  
Nbl1: Neuroblastoma, suppression of tumorigenicity 1  
Nodal: Nodal  
Nog: Noggin  
Pdgfb: Platelet derived growth factor, B polypeptide  
Plat: Plasminogen activator, tissue  
Plau: Plasminogen activator, urokinase  
Runx1: Runt related transcription factor 1  
Runx2: Runt related transcription factor 2 
Serpine1: Serpine (or cysteine) peptidase inhibitor, clade E, member 1  
Sox4: SRY-box containing gene 4  
Stat1: Signal transducer and activator of transcription 1  
Tgfb1: Transforming growth factor β1  
Tgfb1i1: Transforming growth factor β1 induced transcript 1   
Tgfb1i4: Transforming growth factor β1 induced transcript 4 
Tgfb2: Transforming growth factor β2  
Tgfb3: Transforming growth factor β3  
Tgfbi: Transforming growth factor β induced  
Tgfbr1: Transforming growth factor β receptor 1  
Tgfbr2: Transforming growth factor β receptor 2   
Tgfbr3: Transforming growth factor β receptor 3   
Tgif: TG interacting factor 1  
Timp1: Tissue inhibitor of metalloproteinase 1 
Zfhx1a: Zinc finger transcription factor 1a 
PUC18: PUC18 plasmid DNA  
Ppia: peptidylpropyl isomerase A  
Rpl13a: ribosomal protein 13a 
Actb: β-actin  
 
Table A.17: BMP/TGF-β array: The layout of the array is listed, including gene symbol and 
corresponding position on the membrane. The specific array is spotted with BMP and TGF-β members 
and target genes. 
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